

## INDEX

### A

- AAALAC International. *See* Association for Assessment and Accreditation of Laboratory Animal Care International
- Abrin  
toxicity of, 325
- ABSA  
biosafety professional credentialing, 537
- ABSL-3 facilities. *See* Animal biological safety level-3 facilities
- ABSL-4 facilities. *See* Animal biological safety level-4 facilities
- ACAM 2000 vaccine  
candidate vaccine for smallpox, 490–491
- Accidental release of biological agents  
Former Soviet Union's accidental release of anthrax into Sverdlovsk, 10, 52–53, 70–71, 470, 545  
former Soviet Union's accidental release of smallpox in Aralsk, 51–52
- ACCs. *See* Ancillary care centers
- ACIP. *See* Advisory Committee on Immunization Practices
- Activated charcoal  
neurotoxic shellfish poisoning treatment, 370  
trichothecene mycotoxins exposure treatment, 364–365
- Acyclovir  
smallpox treatment, 231
- Adverse events  
anthrax treatment, 470  
anthrax vaccine adsorbed, 469  
eastern equine encephalitis vaccine, 481  
NDBR 105 Q fever vaccine, 477  
NDBR 101 vaccine, 473  
pentavalent botulinum toxoid, 345, 496  
ribavirin therapy, 292–293  
smallpox vaccination, 216, 224, 230–231, 483–490  
TC-83 vaccine, 479  
V3526 vaccine, 481
- Advisory Committee on Immunization Practices  
anthrax treatment recommendations, 470  
smallpox vaccination contraindications, 483
- Afghanistan  
biological weapons program, 14  
Crimean-Congo hemorrhagic fever and, 274  
former Soviet Union's deployment of trichothecene toxins, 356, 545  
former Soviet Union's use of *B mallei* as a biowarfare agent against, 122  
melioidosis and, 151
- Africa. *See also specific countries*  
*Alphavirus* encephalitis and, 242  
Crimean-Congo hemorrhagic fever and, 274  
dengue fever and, 593  
Ebola viruses and, 275–276  
glanders and, 122, 125  
Lassa fever and, 273  
monkeypox and, 224  
plague incidence, 101  
smallpox and, 223  
yellow fever and, 276
- African Americans  
environmental susceptibility to *Aspergillus fumigatus* tests, 6
- Agent Orange  
use in Vietnam, 27
- Agricultural terrorism  
Colorado potato beetle outbreaks during World War II, 27  
economic consequences, 28  
farm-to-food continuum, 27, 29  
livestock vulnerability, 27–28
- Agroterrorism. *See* Agricultural terrorism
- Al Qaeda  
biological weapons program in Afghanistan, 14, 16
- Alaska  
botulism outbreaks, 584  
paralytic shellfish poisoning analysis, 367
- Alcide EXSPORE disinfectant  
description, 529–530
- Algal toxins. *See* Marine algal toxins
- Alibek, Dr. Kenneth  
*Biohazard*, 96  
description of the former Soviet Union's biowarfare program, 338  
weaponization of monkeypox virus by the former Soviet Union, 216  
weaponization of *Y pestis*, 96
- Alimentary toxic aleukia. *See* Trichothecene mycotoxins
- Alkhurma virus  
description, 276  
transmission, 276
- Alphavirus* encephalitis. *See also* Eastern equine encephalitis; Encephalitis; Venezuelan equine encephalitis; Western equine encephalitis  
active immunization, 257–258  
aerosol transmission, 242, 250  
antigenic classification of (table), 245  
antigenicity, 244–246  
budding and release of progeny virus particles, 250  
characteristics of, 242  
clinical manifestations, 252–256, 259  
description, 242–243, 259  
diagnosis, 252–256  
differential diagnosis, 254–255  
endemic and epidemic activity, 246  
environmental factors, 242  
epidemic human pathogens, 242  
epidemiology and ecology, 246–248  
gene sequencing, 244  
genetic manipulation, 259  
genomic RNA, 249  
glycoprotein synthesis, 249–250  
historical background, 243–244  
hospital infection control precautions and, 429  
immune effector mechanisms, 256  
inactivated vaccines, 258  
live vaccines, 244, 256–259  
medical management and prevention, 255–256  
nonviral causes (exhibit), 255  
passive immunization, 256–257  
pathogenesis, 250–252  
potential as a biowarfare agent, 242–244, 254, 256, 259  
prophylaxis, 256–258  
structure and replication of, 242, 248–250  
structure (figure), 249  
transmission, 242  
vaccines, 244, 248, 256–259  
vaccines available for VEE, EEE, and WEE viruses (table), 257  
viral causes of endemic encephalomyelitis (exhibit), 255  
viral infection cycle, 249  
virion structure, 248–250  
worldwide distribution, 242
- American Association of Poison Control Center  
Toxic Exposure Surveillance System report of ricin poisoning, 327

- American Biological Safety Association
  - biosafety risk group assignments, 518
- American Civil War
  - Army ambulance system development, 562
  - glanders and, 123
  - hantaviruses and, 275
  - influence of military medicine on standard medical care practice, 562
  - medical education and, 562
  - melioidosis and, 151
  - use of smallpox as a biological weapon, 220
- American College of Surgeons
  - Advanced Trauma Life Support model, 444, 452
- American Hospital Association
  - chemical and bioterrorism preparedness checklist, 431
- American Society of Crime Laboratory Directors
  - bioforensic standards, 406
- Amherst, Sir Jeffrey
  - introduction of smallpox to Native Americans, 3, 544
- AMLs. *See* Army medical laboratories
- Amnesic shellfish poisoning
  - causative agent, 366, 371
  - clinical manifestations, 371–372, 377
  - diagnosis, 372
  - ingestion route, 371–372
  - inhalation route, 372
  - latency period, 372
  - mechanism of action, 371, 377
  - medical management, 372–373, 377
  - mortality rate, 372
  - potential biowarfare or bioterrorist threat, 373
  - toxin description, 371
- Amoxicillin
  - anthrax treatment, 78–79, 470
  - melioidosis treatment, 157
- Ancillary care centers
  - discharge of patients from, 431
  - expansion of healthcare system into, 430
  - Modular Emergency Medical System and, 430
  - operational flow diagram of casualty evaluation and management using the Modular Emergency Medical System (figure), 430
  - patient medical records and, 431
  - planning considerations, 430–431
  - staffing for, 431
  - suggested minimum staffing per 12-hour shift for a 50-bed nursing subunit (exhibit), 431
- Animal biological safety level-2 facilities. *See also* Laboratory animal care and use program
  - special practices, 531–532
- Animal biological safety level-3 facilities
  - primary barriers for, 524–525
  - secondary barriers for, 528
  - special practices, 531–532
- Animal biological safety level-4 facilities
  - secondary barriers for, 528–529
  - special practices, 531–532
- Animal welfare. *See also Guide for Care and Use of Laboratory Animals*; Laboratory animal care and use program
- Anthrax. *See also B anthracis*
  - active vaccination and, 79–80
  - Aum Shinrikyo cult use of, 12, 48–49, 338–339, 407, 545
  - case studies and lessons learned, 45–46, 48–51
  - causes of infection, 70, 72, 467
  - clinical disease, 74–77, 445
  - composition of anthrax lethal protein toxin (figure), 73
  - cutaneous type, 74–75, 77–79
  - decontamination of people exposed to, 426
  - description, 70, 80, 467
  - diagnosis, 77–78
  - direct fluorescent antibody stain (figure), 78
  - edema toxin, 72–73
  - epidemiology, 71–72
  - exotoxins, 72–73
  - former Soviet Union accidental release of, 10, 52–53, 470
  - funding for studies of, 71
  - gastrointestinal type, 76–79, 582–583
  - German use of infected animals during World War I, 3, 45–46
  - gram stain (figure), 70
  - handling corpses infected with, 436
  - historical background, 70–71
  - hospital infection control precautions and, 429
  - inhalational type, 11, 13, 16, 50–51, 57, 70, 72, 75–76, 78–80, 445, 467–468, 471, 583
  - lethal toxin, 72–74, 467
  - mailings of letters contaminated with, 11, 13, 16, 50–51, 57, 71, 76, 433, 460, 545, 546
  - meningitis and, 77–78
  - military relevance, 70
  - new vaccine research, 469
  - occurrence, 71
  - organism description, 71
  - oropharyngeal type, 76–78, 583
  - PA-based vaccines, 80, 469
  - PA receptor, 74
  - pathogenesis, 72–74
  - postexposure vaccination with chemoprophylaxis, 470–471
  - potential for use as a biowarfare or bioterrorism agent, 468, 583
  - prophylaxis, 13, 79–80, 469–471
  - scanning electron micrograph of spores (figure), 71
  - secondary aerosolization, 426
  - side effects of vaccines, 80
  - supportive therapy, 79
  - transmission of disease, 72, 467–468
  - treatment, 13, 78–80, 469–470
  - underdiagnosing and underreporting of cases, 72
  - vaccine for, 10–11, 71, 467–471
  - wild or domestic animals and, 71–72
- Anthrax vaccine adsorbed
  - adverse events, 469
  - age limitations, 448
  - anthrax prophylaxis, 79–80, 471
  - description, 448, 468
  - dosing guidelines, 448, 468
  - effectiveness of, 448, 468–469
  - vaccination of military personnel, 79
  - vaccine breakthrough occurrence, 468
- Anti-Terrorism Act
  - provisions, 546
- Antibiotic susceptibility testing
  - description, 398
  - Kirby-Bauer disk diffusion, 398
- Antibiotics. *See also specific drugs*
  - anthrax treatment, 78–79, 469–470
  - brucellosis treatment, 190–192
  - emerging antibiotic resistance, 587
  - glanders treatment, 139–140
  - mass prophylaxis and, 433
  - melioidosis treatment, 156–157, 159
  - plague treatment, 107, 111–112
  - postexposure antibiotic prophylaxis regimens (table), 467
  - Q fever treatment, 205
  - tularemia treatment, 174–176
- Antibody tests. *See also* Fluorescent antibody tests

- staphylococcal enterotoxin B, 318
- Antihistamines  
neurotoxic shellfish poisoning treatment, 370–371  
staphylococcal enterotoxin B treatment, 318
- APHL. *See* Association of Public Health Laboratories
- API 20NE  
melioidosis identification kit, 156
- AR 50X: *Army Biological Surety Program*. *See* U.S. Army Biosurety Program
- Arboviruses. *See* *Alphavirus* encephalitis; *specific viruses*
- Arenaviridae*  
agent characteristics, 277  
Argentine hemorrhagic fever, 274, 279, 286, 293, 492, 493–494  
Bolivian hemorrhagic fever, 274, 279, 292–293  
epidemiology, 272–274  
Lassa fever, 273, 279, 285, 292, 493–494, 518  
Machupo virus, 274  
New World group, 273  
Old World group, 273  
ribavirin treatment, 293  
rodent reservoirs, 273  
Sabia virus, 274, 293  
skin rashes, 285  
Whitewater Arroyo virus, 274
- Argentine hemorrhagic fever  
antibody therapy, 293  
clinical manifestations, 279  
description, 274  
disseminated intravascular coagulation and, 286  
ribavirin treatment, 493–494  
transmission, 274  
vaccine for, 290, 492
- Arkansas  
tularemia outbreaks, 169
- Armed Forces Institute of Pathology  
identifying and confirming the presence of biological threats, 392  
Laboratory Response Network responsibilities, 394
- Army Medical Command  
biological select agents and toxins facilities registration, 395
- Army medical laboratories  
bioforensics and, 406  
biological agent testing, 394  
description, 392, 394  
Laboratory Response Network and, 394  
“reach back” capability, 394
- Arthritis  
causative organisms, 313  
smallpox and, 224
- Arthur D. Little Company, Inc.  
glass-filter paper development, 517
- Asia. *See also specific countries*  
*Alphavirus* encephalitis and, 242  
Crimean-Congo hemorrhagic fever and, 274  
dengue fever and, 593  
H5N1 influenza virus and, 590  
paralytic shellfish poisoning and, 367  
plague incidence, 101  
smallpox and, 223  
tularemia and, 168
- ASP. *See* Amnesic shellfish poisoning
- Aspergillus*  
bioterrorism potential, 25
- Aspergillus fumigatus*  
tests of African American susceptibility to, 6
- Association for Assessment and Accreditation of Laboratory Animal Care International  
accreditation for laboratories, 536
- laboratory safety audits, 534
- Association of Official Analytical Chemists  
paralytic shellfish poisoning diagnosis, 368
- Association of Public Health Laboratories  
BSL-3 laboratory practices, 522
- Athamna, A.  
antibiotic-resistant *B anthracis* research, 405
- Atomic Energy Commission  
air filtration technology, 517
- Audits. *See* Laboratory safety audits
- Augmentin  
glanders treatment, 475
- Aum Shinrikyo cult  
attempt to buy Ebola virus, 12, 276, 545  
sarin attack in the Tokyo subway and, 12, 339, 427, 545  
use of anthrax and botulinum toxin in attacks, 12, 16, 22, 48–49, 338–339, 407, 545
- Aura virus. *See* Western equine encephalitis
- Aureomycin  
glanders treatment, 140
- Australia  
*Alphavirus* encephalitis and, 242  
avian influenza and, 589  
brucellosis and, 187  
Hendra virus and, 591  
melioidosis and, 153–155, 157  
Menangle virus and, 592  
paralytic shellfish poisoning and, 367  
Q fever and, 200, 206, 476–477  
smallpox and, 223
- Austria  
tularemia outbreaks, 170
- AVA. *See* Anthrax vaccine adsorbed
- Avian influenza  
outbreaks, 590  
virus isolation, 589–590
- Azaspiracid shellfish poisoning  
bioterrorism and, 366  
causative agent, 366
- Azithromycin  
*C jejuni* infection treatment, 584  
glanders treatment, 140  
melioidosis treatment, 157
- Aztec empire  
introduction of smallpox to, 2

## B

- B anthracis*. *See also* Anthrax  
biosafety risk group assignment, 518  
bioterrorism potential, 22, 583  
Great Britain’s use of as a biological weapon during World War II, 4  
infective dose, 22  
organism description, 71  
Poland’s use of letters contaminated with during World War II, 4  
strain differential, 406–407  
use of “cattle cakes” made of during World War II, 4–5
- B cereus*  
anthrax-like characteristics, 73
- B mallei*. *See also* Glanders  
*B pseudomallei* and, 124–125, 127–128, 135, 137  
description, 136  
first isolation of, 123  
taxonomy, 125  
use in World War II as a biowarfare agent, 122  
warm and moist environments and, 125–126

- B pseudomallei*. *See also* Melioidosis  
*B mallei* and, 124–125, 127–128, 135, 137  
colony morphologies (figure), 149  
description, 148–149  
discovery of, 148  
gene sequencing, 148–149
- BabyBIG. *See* Botulism immune globulin
- Baca, O.G.  
Q fever treatment, 205
- BACTEC  
brucellosis diagnosis, 190
- Baldwin, J.  
*The Eleventh Plague*, 25
- Bang, B.  
brucellosis research, 186
- Barkley, Dr. Emmett  
oral pipetting hazards, 517
- Basic Protocols for Level A (Sentinel) Laboratories  
specific precautions, 395
- Bats  
*Filoviridae* and, 275  
Hendra virus and, 591  
Menangle virus and, 592  
Nipah virus and, 591–592  
severe acute respiratory syndrome and, 591  
Tioman virus and, 592
- Baxby, D.  
cowpox research, 225
- Beal, D.  
clostridial toxin research, 376
- Bennett, M.  
cowpox research, 225
- BIDS. *See* Biological Integrated Detection System
- Billings, John Shaw  
creation of an indexing system for medical publications, 562  
design of Johns Hopkins Hospital building, 562
- Biocrimes  
description and examples, 15
- Biodefense and Pandemic Vaccine and Drug Development Act  
provisions, 575
- Bioforensics  
*B anthracis* strain differentiation, 406–407  
chain of custody and, 406  
military laboratories and, 406  
use of multiple test methods, 406
- Biohazard (Alibek), 96
- Biological Incident Annex  
description, 420–421  
elements of an effective biological response, 421
- Biological Integrated Detection System  
description, 445
- Biological personnel reliability program  
categories of persons who must be enrolled, 552  
continuous monitoring component, 555  
description, 551–552  
drug testing, 554  
final review, 554–555  
initial interview, 552–554  
mandatory disqualifying factors, 552  
medical evaluation, 554  
personnel records review, 554  
personnel security investigation, 554  
potentially disqualifying factors, 552–554  
purpose of, 551
- Biological safety cabinets  
certification of, 524  
class II and class III types, 524  
HEPA filters and, 517  
primary containment and, 516
- Biological Safety Program Manual*  
standard operating procedures, 523
- Biological select agents and toxins  
control over access to, 395  
personnel, physical security, safety, and agent-inventory  
guidelines, 395–396  
storage safety procedures, 396
- Biological terrorism. *See also* Epidemiology of biowarfare and  
bioterrorism; Medical countermeasures against bioterrorism  
Al Qaeda and, 14, 16  
anthrax and glanders events of 1915–1916 case study, 3, 45–46  
anthrax mailings, 11, 13, 16, 50–51, 57, 71, 76, 433, 460, 545, 546,  
583  
Aum Shinrikyo cult and, 12, 16, 48–49, 276, 338–339, 407, 427,  
545  
bioterrorism incidents, 1984–2004 (table), 405  
case studies of events, 45–51  
description, 11  
hoaxes and, 11–12, 16  
improving recognition and surveillance of, 58–60  
increase in incidents of, 11  
Minnesota Patriots Council and, 12  
Rajneesh cult and, 12, 23, 46–48, 545, 584  
recommended therapy for (and prophylaxis against) diseases  
caused by category A biothreat agents (table), 453–454  
ricin and, 324, 325  
stepwise approach to medical management of casualties,  
444–460  
U.S. biological preparedness measures, 12–14
- Biologics Control Act  
biological product standards, 569
- Biosafety. *See also* Biosurety; Laboratory Response Network;  
Laboratory safety audits  
assessing individual risk, 523–524  
Basic Protocols for Level A (Sentinel) Laboratories, 395  
biohazard definition, 516  
biological safety cabinets, 516, 524  
biosafety level terminology, 516, 520–521  
biosafety levels (exhibit), 458  
brucellosis, 186, 190, 192  
BSL-1 facilities, 520–521, 530–531, 534, 535  
BSL-2 facilities, 394–395, 521–522, 530–531, 534–535  
BSL-3 facilities, 395, 521–522, 524–526, 530–531, 534–535  
BSL-4 facilities, 395, 516, 521–522, 524, 527, 530–531, 534–535  
case-fatality rate by disease (table), 519  
Certified Biological Safety Professionals, 537  
credentialing of professionals, 537–538  
description, 516  
documenting safety procedures, 523  
elements of a positive biosafety culture, 537–538  
evolution of, 516–517  
five steps of the risk management process (figure), 533  
glanders, 127, 138, 141  
goals, 516, 537  
human infectious dose by organism (table), 519  
institute personnel (figure), 533  
laboratory animal care and use programs, 536  
laboratory safety audits, 533–535  
management role, 532–535, 537  
measures taken in research to protect laboratory workers, 523  
medical surveillance, 526–527  
melioidosis, 150  
military clinical and field medical laboratories and, 394–395  
objectives of occupational health and safety programs, 527  
“Occupational Exposure to Blood-borne Pathogens,” 395

- physical barriers, 524–525
- primary barriers, 524–525, 551
- primary containment definition and examples, 516
- program elements required for containment and maximum containment laboratories, 523–532
- protecting the community and the environment, 528–529
- Q fever, 200
- Registered Biosafety Professionals, 537
- relationship of risk groups, biosafety levels, practices, and equipment (table), 518
- risk groups, 517–520
- risk management process, 533
- risk mitigation, 523–524
- secondary barriers, 528–529, 551
- secondary containment definition and examples, 516
- Select Agent Program, 535–536
- solid and liquid waste inactivation and disposal, 529–530
- standard and special microbiological practices, 530–532
- training issues, 516, 537
- tularemia, 173, 177
- two-person rule when working with biological select agents and toxins, 536
- universal bloodborne pathogen precautions, 395
- vaccinations and, 527–528
- viral hemorrhagic fevers, 277
- Biosafety in Microbiological and Biomedical Laboratories*
  - animal-holding rooms for BSL-4 facilities, 529
  - areas necessary to establish containment, 551
  - biosafety level terminology, 516, 520–521
  - definition of agents to be handled in each laboratory safety level, 551
  - description, 551
  - primary barriers, 551
  - room fittings and ventilation for ABSL-3 facilities, 528
  - secondary barriers, 551
- Biosecurity. *See also* Biosurety
  - DHHS controls over access to biological select agents and toxins, 395
  - DoD and Army personnel reliability program, 397, 551–555
  - personnel, physical security, safety, and agent-inventory guidelines, 395–396
  - storage of biological select agents and toxins, 396
- BioSense surveillance program
  - description, 60
- Biosurety. *See also* Biosecurity
  - agent accountability, 555–556
  - attenuated strains exempted from regulation (table), 548
  - CDC regulations for entities handling select agents, 548–549
  - diagnostic specimens and, 546–547
  - extremist groups and, 325, 545–546
  - historical background, 544–546
  - immediate reporting requirements for select agents (exhibit), 547
  - regulated amounts of toxins (table), 549
  - regulatory agencies, 546–548
  - regulatory framework for working with and transferring select agents and toxins, 546–547
  - U.S. Army Biosurety Program, 549–556
- BioThrax
  - anthrax prophylaxis, 79–80
- BioWatch program
  - description, 59
- Birds
  - amnesic shellfish poisoning and, 371
  - avian influenza and, 589–590
  - eastern equine encephalitis and, 253
  - western equine encephalitis and, 243, 246
- Black Death. *See also* Plague
  - clinical descriptions by contemporary observers, 93
  - description, 92–93
  - mortality rate, 93
- Bliska, J.B.
  - intracellular replication in plague, 105
- Blue Book. See Medical Management of Biological Casualties Handbook*
- BMBL. *See Biosafety in Microbiological and Biomedical Laboratories*
- Boccaccio, Giovanni
  - Decameron* description of the plague, 93
- Bolivian hemorrhagic fever
  - antibody therapy, 293
  - clinical manifestations, 279
  - description, 274
  - ribavirin treatment, 293
  - transmission, 274
  - vaccine for, 290
- Borreliosis. *See* Lyme disease
- Borzenkov, V.M.
  - genetic engineering research, 405
- BOTOX
  - use by an unlicensed physician, 344
- Botulinum antitoxin, heptavalent, equine
  - botulism treatment, 343–344, 497
- Botulinum antitoxin F(ab')
  - botulism treatment, 343–344, 497
- Botulinum immune globulin
  - early treatment with, 344
- Botulinum toxin. *See also* *C botulinum*
  - antigenic types, 584
  - antitoxin treatment, 343–344, 346, 571, 584
  - assassination of Reinhard Heydrich and, 4
  - Aum Shinrikyo cult's use of, 12, 16, 22, 48–49, 339
  - botulinum neurotoxin A composition (figure), 338
  - classic symptoms, 341, 346
  - clinical manifestations, 340–341, 344, 445, 584
  - clinically relevant signs of bioterrorist attack, 344
  - cultures in foodborne botulism, 342
  - description of the agent, 339–340
  - diagnosis, 341–344, 346
  - differential diagnosis, 341
  - early symptoms, 340
  - early treatment importance, 344
  - electrophysiological studies, 341–342
  - foodborne ingestion route of infection with, 338, 340, 342, 344
  - foods associated with, 584
  - future research recommendations, 346
  - historical background, 338–339
  - incubation period, 340
  - inhalation route of exposure, 341–343
  - lethal dose, 340, 584
  - mass casualty event model, 339, 345
  - mortality rate, 338, 340, 343, 346, 584
  - neurotoxin production, 340
  - new vaccine research, 346, 496–497
  - notification of public officials and, 341
  - paralysis and, 339–341, 344
  - pathogenesis, 340
  - potential use as a biowarfare or bioterrorism agent, 338, 340, 344, 346
  - prophylaxis, 344–346, 497
  - ricin and, 324
  - secondary infections and, 340
  - supportive care for infection with, 343, 346
  - toxin assays in foodborne botulism, 342
  - treatment, 343–346
  - vaccines, 345–346, 495–497, 571

- wound botulism, 342–343
  - Botulism. *See* Botulinum toxin
  - Botulism immune globulin
    - botulism treatment for infants and children, 343, 346, 497
  - Bouquet, Col. Henry
    - introduction of smallpox to Native Americans, 3
  - Bovine spongiform encephalitis
    - economic consequences of, 28
  - Boylston, Dr. Zabdiel
    - smallpox vaccination and, 227
  - BPRP. *See* Biological personnel reliability program
  - Brazil
    - castor bean cultivation, 324
    - Sabia virus, 274
  - Brevetoxins. *See* Neurotoxic shellfish poisoning
  - Bruce, David
    - brucellosis research, 186
  - Brucellosis
    - arthritis and, 189, 192
    - chronic type, 186, 189
    - clinical manifestations, 186, 189–190, 192, 475
    - course of disease, 189
    - description, 186, 192, 475
    - diagnosis, 190, 192
    - endocarditis and, 191
    - epidemiology, 187
    - genitourinary tract infection and, 189
    - hepatitis and, 189
    - historical background, 186
    - hospital infection control precautions and, 429
    - incubation period, 189
    - infectious agent, 186–187
    - laboratory-acquired infections, 186
    - laboratory safety issues, 186, 190, 192
    - lung infections and, 189
    - military role in research, 186
    - minimum inhibitory concentration breakpoint ranges (table), 191
    - mortality rates, 189, 192
    - occupational exposure, 187
    - pathogenesis, 188
    - potential for use as a biological weapon, 186
    - prophylaxis, 192
    - serologic tests, 190
    - sites of infection, 189–190
    - symptoms and signs (table), 189
    - taxonomy, 186
    - transmission, 186–187, 192, 475
    - treatment, 190–192, 476
    - typical host specificity (table), 187
    - vaccines and, 188, 476
    - worldwide distribution of, 186
  - BSATs. *See* Biological select agents and toxins
  - BSCs. *See* Biological safety cabinets
  - Bubonic plague
    - clinical manifestations, 105
    - description, 92
    - mortality rate, 105
    - secondary pneumonic plague and, 92, 105
    - symptoms, 92
  - Buffalopox
    - clinical manifestations, 220, 225
  - Bulgaria
    - tularemia and, 169, 173
  - Bunyaviridae*
    - agent characteristics, 277–278
    - Crimean-Congo hemorrhagic fever, 274, 279, 285–287, 293, 493–494
  - hantavirus pulmonary syndrome, 274–275
  - hantaviruses, 274–275, 279–280
  - Korean hemorrhagic fever, 275, 293
  - Puumala virus, 275
  - ribavirin treatment, 293
  - Rift Valley fever virus, 274, 277, 279, 286, 293, 492
  - Seoul virus, 275
  - vectors, 274
  - Burgdorfer, Dr. Willy
    - Lyme disease research, 585
  - Burnet, Frank Macfarlane
    - Q fever research, 200
  - Burr, Sen. Richard
    - Biodefense and Pandemic Vaccine and Drug Development Act, 575
  - Burrows, W.D.
    - review of potable water threats, 27
  - Bush, Pres. George W.
    - Homeland Security Presidential Decision-Directive 10, 13–14
    - Project Bioshield, 14, 574
  - Butler, Thomas
    - conviction for handling plague samples, 546
  - Buxton, D.
    - clostridial toxin research, 376
  - BWC. *See* Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction
- ### C
- C-84 vaccine
    - administration, 480
    - aerosol challenge and, 479
    - at-risk laboratory workers and, 480
    - components, 480
    - description, 479
    - Venezuelan equine encephalitis, 258, 479–480
  - C botulinum*. *See also* Botulinum toxin
    - antigenic types of neurotoxins, 339–340
    - Aum Shinrikyo cult use of, 12, 22, 339
    - bioterrorism potential, 22–23, 338, 340, 344, 346
    - botulism intoxication cause, 22
    - Czechoslovakia's use of to assassinate Reinhard Heydrich, 4
    - description of the agent, 339–340
    - human lethal dose, 22
    - incubation period, 22
    - milk supply contamination, 22–23
    - mortality rate from foodborne botulism, 22
    - technical barriers in isolating, 339
    - treatment, 22, 584
  - C burnetii*
    - description, 201
    - isolation of, 200
    - Q fever cause, 200
  - C jejuni*
    - antibiotic resistance, 23, 584
    - chronic sequelae, 23
    - identification of, 583
    - scanning electron microscope image (figure), 583
    - symptoms of infection, 583
    - transmission, 23
    - treatment, 583–584
    - virulence factors, 583
  - C parvum*
    - water supply issues, 27
  - C perfringens*. *See also* Clostridial toxins
    - crystal structure (figure), 375

- description, 373
- major toxin types (table), 373
- toxin types and diseases (table), 373
- California
  - amnesic shellfish poisoning and, 371
  - botulinum treatment product availability, 343, 497
  - castor bean cultivation, 324
  - ehrlichiosis and, 586
  - Mediterranean fruit fly release, 27
  - plague epidemics, 102
  - tularemia outbreaks, 168, 173
  - western equine encephalitis and, 242–243
  - Whitewater Arroyo virus, 274
- Cambodia
  - former Soviet Union's deployment of trichothecene toxins, 7, 25, 356, 545
- Camelpox
  - Iraqi research with as part of the biological warfare program, 221
- Campylobacter*. *See also C jejuni*
  - bioterrorism potential, 23
  - insect transmission, 23
  - water supply issues, 27
- Canada
  - Borrelia*-caused outbreaks, 586
  - eastern equine encephalitis and, 243–244
  - Lassa fever and, 273
  - paralytic shellfish poisoning and, 369
  - SARS outbreak, 427–430, 437, 590
  - use of secret open-air tests of pathogens after World War II, 4–5
  - western equine encephalitis and, 243
- Canadian Science Centre for Human and Animal Health
  - standard liquid biowaste disposal process, 530
- Candid #1 vaccine
  - Argentine hemorrhagic fever, 290, 492
  - Junin virus, 290
- Carus, W.S.
  - biocrimes analysis, 15
- Caspases
  - staphylococcal enterotoxin B treatment, 314
- Castor beans. *See also Ricin*
  - agricultural production of, 324, 332
  - lubricating and laxative effects of oil from, 324
  - nonlethal uses for, 324
  - toxicity of, 324
  - tropical and subtropical areas and, 324, 332
- Cat scratch disease
  - plague differential diagnosis, 109
- Cats
  - plague and, 99, 100
- Cattle. *See also Livestock; specific diseases*
  - brucellosis and, 186
  - E coli* 0157:H7 and, 24
  - Q fever and, 201, 203, 206
- Cavanaugh, Lt. Col. Dan C.
  - plague research, 94
- CCHF. *See* Crimean-Congo hemorrhagic fever
- CDC. *See* Centers for Disease Control and Prevention
- Cefazolin
  - anthrax treatment, 79
- Ceftazidime
  - glanders treatment, 140
  - melioidosis treatment, 156–157, 159
- Center for the Nonproliferation Studies
  - countries known to possess biological or toxin weapons, 545
- Centers for Disease Control and Prevention
  - aerosol vulnerability tests conducted in San Francisco and, 6
  - anthrax mailing investigation, 50, 71, 433, 545
  - anthrax treatment recommendations, 470
  - attenuated virus and bacteria strains exempted from regulation (table), 548
  - B pseudomallei* safe handling, 150
  - biological select agents and toxins facilities registration, 395
  - “Biosafety in Microbiological and Biomedical Laboratories,” 396
  - biosafety levels, 423
  - BioSense surveillance program, 60
  - botulinum equine antitoxin availability, 343
  - botulinum toxin assays, 342
  - clinical description of brucellosis, 190
  - clostridial toxins and, 374
  - coordination of civilian medical countermeasure development, 14
  - critical agents for health preparedness (table), 447
  - diagnostic specimen identification, 547
  - free planning software for large-scale smallpox prophylaxis clinics, 434, 436
  - glanders and, 131, 141–142
  - immediate reporting requirements for select agents (exhibit), 547
  - laboratory criteria for diagnosing brucellosis, 190
  - Laboratory Response Network for Bioterrorism, 13, 392, 394, 397, 408, 457, 522
  - laboratory safety audits, 534
  - laboratory tests for plague, 110
  - list of biological threat agents, 22
  - Morbidity and Mortality Weekly Report, 101
  - National Electronic Disease Surveillance System, 522
  - paralytic shellfish poisoning outbreaks, 367
  - pentavalent botulinum toxoid availability, 345, 495
  - prophylaxis for plague, 112
  - real-time polymerase chain reaction assay development, 404
  - regulated amounts of toxins (table), 549
  - regulations for entities handling select agents, 548–549
  - regulatory framework for working with and transferring select agents and toxins, 546
  - research effort focus, 522
  - responsibility for food safety, 29
  - ricin detection and, 331
  - ricin mailing investigation, 51
  - ricin's use as a toxin and, 325
  - S typhimurium* outbreak in The Dalles, OR, 47
  - Select Agent Program, 535–536
  - Smallpox Diagnosis and Evaluation page on the CDC Web site, 225
  - smallpox preparedness program, 14
  - Smallpox Response Plan, 449, 459
  - smallpox vaccination contraindications, 483
  - Smallpox Vaccine Injury Compensation Program, 449
  - Strategic National Stockpile, 13–14, 421, 432–433, 459
  - tularemia threat and, 168
  - viral hemorrhagic fever biosafety issues, 288
  - viral hemorrhagic fever classification as bioweapon agent, 276
  - waterborne pathogens list, 27
  - West Nile virus outbreak investigation, 53
- Central America. *See also specific countries*
  - Venezuelan equine encephalitis and, 243–244, 248
- Central Intelligence Agency
  - biological weapon development, 5
  - destruction of toxin samples, 8
- Cephalothin
  - anthrax treatment, 79
- CFT. *See* Complement fixation test
- Chancroid

- plague differential diagnosis, 109–110
- Chapin, C.W.
  - smallpox research, 223
  - tularemia research, 168
- Chemical and Biological Incident Response Force
  - description, 422
- Chemical Corps
  - alerting in biowarfare events, 456
- Chemical Weapons Convention
  - ricin and, 325
- Chikungunya virus. *See* *Alphavirus* encephalitis
- Children. *See* Infants and children
- China
  - allegations against the United States for using biological warfare during the Korean War, 6–7
  - avian influenza and, 589–590
  - brucellosis and, 187
  - early smallpox vaccination program, 227
  - Japan's biological warfare program against China during World War II, 3–4, 220
  - Japan's deliberate introduction of plague to cities during World War II, 96
  - Korean hemorrhagic fever and, 275
  - pneumonic plague epidemic, 93–94
  - severe acute respiratory syndrome and, 590
  - World War II glanders prevalence in horses, 126
- Chloramphenicol
  - anthrax treatment, 79
  - melioidosis treatment, 156
  - plague treatment, 111–112, 474
  - tularemia treatment, 175, 471
- Cholera
  - biotypes, 581
  - clinical manifestations, 581
  - historical background, 580–581
  - infective dose, 581
  - transmission, 581
  - treatment, 581
  - typical conditions that can lead to an outbreak (figure), 581
  - vaccine, 581
- Cidofovir
  - cytomegalovirus treatment, 231–232, 491
  - smallpox and monkeypox treatment, 231–232, 488, 491–492
- Ciguatera fish poisoning
  - bioterrorism and, 366
  - causative agent, 366
  - clinical manifestations, 366
  - description, 366
- Cilastatin
  - melioidosis treatment, 157, 159
- Ciprofloxacin
  - anthrax treatment, 78, 470–471
  - C jejuni* infection treatment, 584
  - empirical administration of, 455
  - glanders treatment, 139–140, 475
  - melioidosis treatment, 157–158, 475
  - plague treatment, 111
  - tularemia prophylaxis, 176, 473
  - tularemia treatment, 175
- Clarithromycin
  - Q fever treatment, 205
- Cleghorn, G.
  - brucellosis research, 186
- Clindamycin
  - anthrax treatment, 79
- Clinical and Laboratory Standards Institute
  - antibiotic susceptibility testing, 398
- Clinical laboratories
  - description, 522
- Clinical Laboratory Standards Institute
  - standards for brucellosis testing, 190–191
- Clinical microbiological methods
  - bacteriological media for isolation, 398
  - biological threat agent identification, 397–398
- Clostridial toxins. *See also C perfringens*
  - clinical and physical properties, 374–375
  - clinical manifestations, 375, 377
  - epsilon toxin, 374–377
  - gangrene and, 373–374
  - historical background, 373–374
  - mechanism of action, 374–375
  - medical management, 375–376
  - mortality rate, 375, 377
  - natural occurrence, 374
  - pathogenesis, 373
  - potential biowarfare or bioterrorism threat, 374
  - toxin description, 374–375
  - treatment, 374
  - vaccine for animal use, 375–377
  - virulence factors, 374
- CLSI. *See* Clinical Laboratory Standards Institute
- CM4884 vaccine
  - at-risk laboratory workers and, 480
  - western equine encephalitis, 480–481
- Code of Federal Regulations
  - infected human remains transport, 436
- Cohorting of patients
  - local response to a biological attack and, 429–430
- College of American Pathologists
  - registration and inspection of laboratories, 547
- College of the Holy Cross
  - hepatitis A virus outbreak, 25, 27
- Colombia
  - equine vaccination for Venezuelan equine encephalitis (figure), 248
  - Venezuelan equine encephalitis and, 242–243
  - Venezuelan equine encephalitis epizootic (figure), 246
- Colorado
  - Department of Public Health and Environment identification of *E coli* 0157:H7 outbreak, 24
- Colorado potato beetle
  - World War II outbreaks, 27
- Complement fixation test
  - glanders, 137–138
  - Q fever, 204
  - smallpox, 226
- Computed tomography
  - glanders, 137
  - inhalational anthrax, 78
  - melioidosis (figures), 155
- Conjunctivitis
  - staphylococcal enterotoxin B and, 318
- Consequence management
  - biological agent attractiveness for terrorists, 424
  - coordination issues, 416
  - legal issues, 436–437
  - local response, 424–436
  - national response, 416–424
  - recognition of overt attacks, 424
- Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction
  - botulinum toxin and, 338
  - U.S. Department of State report on biological warfare

- programs in violation of, 15
  - Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction
    - development of, 7
    - former Soviet Union and, 9
    - ricin and, 325
    - signatories, 7–8, 15, 122–123, 545
  - Corticosteroids
    - staphylococcal enterotoxin B treatment, 314
  - Cowpox
    - clinical manifestations, 220, 225
  - Cox, H.R.
    - Q fever research, 200
  - Coxiellosis. *See* Q fever
  - Crimean-Congo hemorrhagic fever
    - cutaneous ecchymosis (figure), 280
    - description, 274
    - disseminated intravascular coagulation and, 279, 285–286
    - hospital-centered outbreaks, 274
    - passive immunotherapy, 494
    - ribavirin treatment, 293, 493
  - Cruikshank, George
    - Vaccination Against Smallpox political cartoon (figure), 561
  - Cryptosporidium*
    - duration of illness, 24
    - food and waterborne illness and, 24
    - sources, 24
    - water supply issues, 27
  - Cuba
    - allegations against the United States of a biological attack with a crop pest insect, 8
    - alleged import by the United States of glanders-infected horses into, 123
  - Cutaneous anthrax
    - clinical disease characteristics, 74–75
    - diagnosis, 77–78
    - differential diagnosis, 77–78
    - lesions (figure), 75
    - malignant edema and, 75
    - mortality rate, 75
    - treatment, 78–79
  - Cytokine inhibitors
    - staphylococcal enterotoxin B treatment, 314
  - Cytomegalovirus
    - treatment, 231–232
  - Czechoslovakia
    - use of botulinum toxin to assassinate Reinhard Heydrich, 4
- D**
- Dairy foods. *See also* Milk supply
    - brucellosis and, 186–187
  - Daschle, Sen. Tom
    - anthrax mailings to the office of, 50
  - Decameron* (Boccaccio)
    - description of the plague, 93
  - Decontamination
    - aerosol delivery devices and, 451–452
    - announced threats and, 451
    - anthrax and, 426
    - glanders and, 141
    - notification of public health personnel and, 451
    - suspicious packages and, 451
    - telephoned threats and/or empty letters and, 451
    - trichothecene mycotoxins and, 364
  - Defense Against Weapons of Mass Destruction Act
    - Domestic Preparedness Program, 416–417
    - provisions, 416–417
  - Delaware
    - eastern equine encephalitis outbreak, 243
  - DELFLA. *See* Dissociation-enhanced lanthanide fluorescence immunoassay
  - Democratic Republic of the Congo
    - Crimean-Congo hemorrhagic fever and, 274
    - Marburg virus, 275
    - monkeypox and, 224–225
    - smallpox outbreaks, 216
  - Dengue fever
    - Aedes albopictus* mosquito feeding on a human host (figure), 594
    - clinical manifestations, 280, 593
    - description, 276, 593
    - global emergence of, 593–594
    - jungle cycle, 276
    - transmission, 276, 593
    - tropical and subtropical regions and, 593
    - vaccine for, 290
    - viral subtypes, 593
  - Dengue hemorrhagic fever / dengue shock syndrome
    - antibody-dependent enhancement and, 593
    - clinical manifestations, 278, 280, 593
    - description, 276
    - immune enhancement and, 593
    - pathogenesis, 593
  - Denmark
    - amnesic shellfish poisoning and, 371
  - Dexamethasone
    - ricin treatment, 332
    - trichothecene mycotoxins exposure treatment, 365
  - DHF/DSS. *See* Dengue hemorrhagic fever / dengue shock syndrome
  - DHHS. *See* U.S. Department of Health and Human Services
  - di Coppo di Stefano Buonaiuti, Marchionne
    - description of the plague, 93
  - Diabetes mellitus
    - melioidosis and, 148, 153, 158
    - TC-83 vaccine and, 479
  - Diarrheic shellfish poisoning
    - bioterrorism and, 366
    - causative agent, 366
  - Diatoms. *See* Amnesic shellfish poisoning
  - DIC. *See* Disseminated intravascular coagulation
  - Difluoromethylornithine
    - ricin treatment, 332
  - Dihydrocodeinone
    - staphylococcal enterotoxin B treatment, 318
  - Dilger, Anton
    - anthrax and glanders events of 1915–1916 and, 45, 122
  - Diphenhydramine
    - trichothecene mycotoxins exposure treatment, 365
  - Disinfectants
    - general household types, 530
    - solid and liquid waste disposal, 529–530
  - Disseminated intravascular coagulation
    - Argentine hemorrhagic fever and, 286
    - cause of, 288
    - Crimean-Congo hemorrhagic fever and, 279, 286
    - Ebola viruses and, 280, 286
    - Korean hemorrhagic fever and, 286
    - Marburg virus and, 280, 286
    - Rift Valley fever virus and, 286
    - viral hemorrhagic fevers and, 285–286
  - Dissociation-enhanced lanthanide fluorescence immunoassay
    - description, 401

- Division of Occupational Health and Safety
  - National Biosafety and Biocontainment Training Program, 537
- Dixon, C.W.
  - smallpox research, 223
- Dobutamine
  - paralytic shellfish poisoning treatment, 369
- Domestic Preparedness Program
  - description, 416–417
- Domoic acid. *See* Amnesic shellfish poisoning
- Donkeys
  - glanders and, 122, 126, 128–130
- Downs, C.M.
  - tularemia vaccine, 176
- Doxycycline
  - anthrax treatment, 78–79, 470–471
  - brucellosis treatment, 191–192, 476
  - empirical administration of, 455
  - glanders treatment, 139–140, 475
  - meliodosis treatment, 156–158, 475
  - plague treatment, 111, 474
  - Q fever treatment, 205, 478
  - tularemia prophylaxis, 176
  - tularemia treatment, 175
- Dried, Calf Lymph Type vaccine
  - smallpox vaccination, 229, 449, 482–483
- Droes. *See* Glanders
- Dryvax. *See* Dried, Calf Lymph Type vaccine

## E

- E coli* 0157:H7
  - clinical manifestations, 584
  - hemolytic uremic syndrome and, 23–24, 584
  - mortality rate, 584
  - primary source for, 584
  - waterborne outbreaks, 24, 27
- Eastern equine encephalitis
  - components of the virus complex, 244
  - description, 242
  - diagnosis, 253
  - enzootic transmission, 244
  - incidence of human infection, 253
  - incubation period, 253
  - isolation of, 242
  - morbidity, 253
  - mortality rate, 242, 253
  - neurological sequelae, 253
  - passive immunization, 256–257
  - pathogenesis, 250
  - vaccines, 244, 256, 258–259, 481
  - vaccines available for VEE, EEE, and WEE viruses (table), 257
- Eastern equine encephalitis vaccine
  - adverse events, 481
  - at-risk laboratory workers and, 481
  - components, 481
  - description, 481
- Eastern Europe. *See also specific countries*
  - glanders and, 122, 125
- Ebola viruses
  - agent characteristics, 278
  - Aum Shinrikyo cult's attempt to buy, 12, 276, 545
  - biosafety risk group assignment, 518
  - clinical manifestations, 278–279
  - cynomolgus monkeys and, 275, 282
  - disseminated intravascular coagulation and, 280, 285–286
  - heparin treatment, 293
  - infection of endothelial cells, 282
  - media attention, 272
  - mortality rate, 272, 275, 294
  - passive immunotherapy, 494
  - pathogenesis, 272
  - petechial skin rash, 285
  - Sudan type, 275, 278–279
  - transmission electron micrograph (figure), 277
  - vaccine for, 292, 492
  - weaponization of, 274
  - Zaire type, 275, 278–279
- Ecker, D.J.
  - TIGER research, 405
- ECL. *See* Electrochemiluminescence
- Ecuador
  - castor bean cultivation, 324
  - Venezuelan equine encephalitis and, 243, 252
- Eczema vaccinatum
  - adult with (figure), 488
  - contact precautions, 487
  - description, 485
  - infant with (figure), 487
  - mortality rate, 485
  - treatment, 230
- Edghill-Smith, Y.
  - smallpox vaccination research, 228–229
- EEE. *See* Eastern equine encephalitis
- Egypt
  - meliodosis as a potential biowarfare agent, 150
- Ehrlich, Paul
  - ricin research, 324
- Ehrlichiosis
  - causative agent, 586
  - clinical manifestations, 586–587
  - mortality rate, 586
- Eigelsbach, H.T.
  - tularemia vaccine, 176
- El Salvador
  - West Nile virus and, 594
- Elderly persons
  - amnesic shellfish poisoning and, 372
  - eastern equine encephalitis and, 253
  - western equine encephalitis and, 254
- Electrochemiluminescence
  - agents effective for, 401
  - description, 400
  - field-ready system for, 401
  - Ru label, 400–401
- Electronic Surveillance System for the Early Notification of Community-based Epidemics
  - description, 59
- The Eleventh Plague* (Marr and Baldwin), 25
- ELISA. *See* Enzyme-linked immunosorbent assay
- Emergencies Involving Chemical or Biological Weapons Act
  - provisions, 417
- Emergency Preparedness Resource Inventory software, 431–432
- Emerging infectious disease threats. *See also specific diseases*
  - arthropod-borne viruses, 592–595
  - avian influenza, 587–590
  - bacterial diseases, 580–587
  - bioterrorism incidents, 1984–2004 (table), 405
  - challenges for the military clinical or field laboratory, 405–406
  - definition, 580
  - factors contributing to emergence, 580
  - foodborne diseases, 582–584
  - future threats, 596–597
  - genetically engineered threats, 595–596
  - nonstate actors and, 405
  - pandemic influenza, 587–590

- paramyxoviruses, 591–592
  - reemerging pathogens, 580
  - severe acute respiratory syndrome, 590–591
  - tick-borne diseases, 585–587
  - viral diseases, 587–595
  - waterborne diseases, 580–582
  - zoonotic diseases and, 580
  - Encephalitis. *See also Alphavirus encephalitis*
    - monkeypox and, 225
    - smallpox and, 224
    - smallpox vaccination complication, 228
  - Endocarditis
    - brucellosis and, 191
    - Q fever and, 203, 205, 478
  - Environmental Protection Agency
    - decontamination solution registration, 426
    - emergency support functions, 418
  - Enzyme-linked immunosorbent assay
    - advantage of, 400
    - anthrax, 79–80
    - botulinum toxin, 343
    - brucellosis, 190, 192
    - description, 399–400
    - glanders, 137–139
    - Q fever, 204
    - smallpox, 226
  - EPA. *See* Environmental Protection Agency
  - Epidemics
    - baseline rates of disease and, 40
    - chain of custody and, 44–45
    - clues to an unnatural event, 41–43
    - counting cases, 43
    - dead animals and, 42
    - deciding whether an outbreak exists, 43
    - definition, 40
    - developing a hypothesis, 44
    - developing exposure data, 44
    - direct evidence and, 42–43
    - downwind plume pattern and, 42
    - ensuring the safety of public health personnel, 45
    - epidemiological triangle, 40
    - establishing a case definition, 43
    - formulating a conclusion, 44
    - goals of an outbreak investigation (exhibit), 43
    - higher morbidity or mortality than is expected and, 41
    - implementing control measures, 44
    - large number of casualties and, 41
    - multiple events and, 42
    - naturally occurring outbreak investigation compared with unnaturally occurring outbreak investigation, 44
    - outbreak investigation steps, 43–45
    - point source outbreak curve and, 42
    - preparing for, 43
    - protected individuals and, 42
    - recognition of the event, 40–41
    - reverse or simultaneous spread and, 42
    - seeking a definitive diagnosis, 43
    - testing and evaluating the hypothesis, 44
    - typical continuous common source outbreak epidemic curve (figure), 44
    - typical propagated (second transmission) outbreak epidemic curve (figure), 44
    - uncommon diseases and, 41
    - unusual disease manifestation and, 42
  - Epidemiological assessment tool
    - criteria types, 56
    - cut-off scores for nonconclusive criteria, 57
    - description, 56–57
    - epidemiological assessment and evaluation of case study outbreaks (table), 58
  - Epidemiology of biowarfare and bioterrorism
    - accidental release of biological agent case studies, 51–53
    - bioterrorism event case studies, 45–51
    - epidemiological assessment and evaluation of case study outbreaks (table), 58
    - epidemiology of epidemics, 40–45
    - Grunow and Finke’s epidemiological assessment tool, 56–58
    - improving recognition and surveillance of bioterrorism, 58–60
    - studies of natural outbreaks for potential bioweapon use, 53–56
    - syndromic surveillance, 59–60
    - underreporting of infectious disease outbreaks, 59
  - Equids. *See* Donkeys; Horses; Mules
  - Equine antitoxin
    - allergic reactions, 344
    - botulinum toxin treatment, 344
    - preexposure prophylaxis and, 344
    - side effects, 343
  - Equine morbillivirus. *See* Hendra virus
  - Equinia. *See* Glanders
  - Ergonul, O.
    - Crimean-Congo hemorrhagic fever research, 493
  - Erythromycin
    - anthrax treatment, 79
    - C jejuni* infection treatment, 583–584
  - ESSENCE. *See* Electronic Surveillance System for the Early Notification of Community-based Epidemics
  - Ethical and legal dilemmas in biodefense research. *See also* Legal issues
    - animal efficacy rule, 560, 574
    - current movements in the regulatory environment, 573–575
    - historical background, 561–569
    - impact of regulating agencies on strategic research, 569
    - Operation Whitecoat, 6, 565–567
    - options for fulfilling mission and ethical responsibilities to military personnel, 572–573
    - Public Health Security and Bioterrorism Preparedness and Response Act, 573–574
    - unintended consequences of federal regulations governing the conduct of human subjects research, 560–561
    - War Research Service and, 562, 565
  - Ethiopia
    - castor bean cultivation, 324
  - Europe. *See also specific countries*
    - Alphavirus encephalitis* and, 242
    - Crimean-Congo hemorrhagic fever and, 274
    - early smallpox vaccination program, 227
    - H7N7 influenza virus and, 590
    - Lassa fever and, 273
    - Lyme disease and, 585
    - paralytic shellfish poisoning and, 367
    - smallpox and, 223, 229
    - tularemia and, 168, 170
  - Evans, A.C.
    - brucellosis research, 186
- ## F
- F philomiragia*
    - F tularensis* and, 168
  - F tularensis*. *See also* Tularemia
    - biosafety risk group assignment, 518
    - description, 55, 168
    - F philomiragia* and, 168
    - Japan’s experimentation with as a biological weapon, 168

- Kosovo outbreak, 55–56, 168, 170
- Martha's Vineyard, MA, outbreak, 54–55, 170, 173
- F1-V vaccine
  - plague, 103, 112–113, 474
- Farcy. *See* Glanders
- FBI. *See* Federal Bureau of Investigation
- FDA. *See* U.S. Food and Drug Administration
- FDA Kefauver-Harris Drug Amendments
  - drug regulation system, 569
- Federal Bureau of Investigation
  - S typhimurium* outbreak in The Dalles, OR, 23, 47
- Federal Drug Act
  - "fast tracking" new drugs, 573–574
- Federal Insecticide, Fungicide, and Rodenticide Act
  - decontamination solution registration with the EPA, 426
- Federal Radiological Emergency Response Plan
  - National Response Plan integration of, 417
- Federal Response Plan
  - National Response Plan integration of, 417
- Feldman, K.A.
  - Martha's Vineyard tularemia outbreak, 55, 170
- Fetal vaccinia
  - description, 490
  - infant with (figure), 489
- Filoviridae*
  - agent characteristics, 278
  - bats and, 275
  - Ebola viruses, 12, 275, 278, 282, 285–286, 292–294, 492, 494, 518, 545
  - electron microscopy, 275
  - Marburg virus, 275, 278, 285–286, 292–293, 518
  - mortality rates, 279–280
  - natural history of, 275
  - ribavirin treatment, 293
- Finke, E.J.
  - epidemiological assessment tool, 56–58
- Finlay, Carlos
  - yellow fever research, 276
- Flaviviridae*
  - agent characteristics, 278
  - Alkhurma virus, 276
  - dengue fever, 276, 280, 593–594
  - Kyasanur forest disease, 276, 290
  - Omsk hemorrhagic fever, 276
  - Philippine hemorrhagic fever, 276
  - ribavirin treatment, 293
  - yellow fever, 276, 280, 450, 492
- Fleas
  - Hms virulence factor, 104
  - plague and, 98, 100–101
- Fletcher, W.
  - melioidosis research, 148
- Flies
  - Bunyaviridae* and, 274
  - tularemia and, 169–170
- Florida
  - gastroenteritis outbreak from a contaminated recreational water fountain, 27
  - neurotoxic shellfish poisoning outbreak, 370
  - red tides, 365
- Flow cytometry
  - applications for, 401
  - assay performance characteristics, 402
  - commercially available platform for, 402
  - description, 401
  - technique for, 401–402
- Fluorescent antibody assay
  - Q fever, 204
- Fluorescent antibody tests
  - brucellosis (figure), 191
  - plague, 110, 113
- FMD. *See* Foot and mouth disease
- Fontana, J.
  - antibiotic susceptibility test research, 398
- Food, Drug, and Cosmetics Act
  - Food and Drug Administration regulations originating in, 560
  - regulation of biologics, 569
- Food and Agriculture Organization
  - brucellosis treatment recommendation, 192
- Food and water security
  - food distribution system and, 29
  - rational employee hiring and accountability procedures and, 29
  - strategies to counter threats, 29
  - vulnerabilities for contamination, 29
- Foodborne, waterborne, and agricultural diseases
  - agricultural terrorism, 27–28
  - B anthracis*, 22, 583
  - C botulinum*, 22–23, 584
  - Campylobacter*, 23, 583–584
  - cholera, 580–581
  - clostridial toxins, 373–376
  - Cryptosporidium*, 24
  - E coli* 0157:H7, 23–24, 584
  - food and water security, 29
  - food and waterborne disease pathogens (table), 26
  - hepatitis A virus, 24–25
  - Legionnaire's disease, 582
  - Listeria monocytogenes*, 23
  - marine algal toxins, 365–373
  - parasites, 25
  - pathogen summary, 26
  - Salmonella*, 23, 584
  - Shigella*, 24
  - staphylococcal enterotoxin B role in food poisoning, 312
  - trichothecene mycotoxins, 25
  - tularemia, 169
  - Vibrio* species diseases, 580–582
  - water supply concerns, 26–27
- Foot and mouth disease
  - agricultural and food losses from outbreaks of, 28
  - relevance as a biological weapon, 28
- Former Soviet Union
  - accidental release of anthrax into Sverdlovsk, 10, 52–53, 70–71, 470, 545
  - accidental release of smallpox in Aralsk, 51–52
  - allegations against the United States of using biological warfare during the Korean War, 6–7
  - Alphavirus* encephalitis outbreak, 242
  - anthrax vaccination, 79, 469
  - assassination of Georgi Markov, 9
  - attack on Vladimir Kostov, 9–10
  - Biopreparat establishment and mission, 9, 338
  - Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction and, 545
  - Crimean-Congo hemorrhagic fever and, 274
  - historical background of biological warfare program, 8–10, 544–545
  - melioidosis as a potential biowarfare agent, 150
  - plague incidence, 101
  - production and storage of smallpox virus as a strategic weapon, 216, 220, 233
  - Q fever vaccine, 206, 477–478

- ricin as a biological weapon and, 325
  - testing of botulinum-filled weapons, 338
  - toxin weapon development for use by Warsaw Pact intelligence services, 9
  - trichothecene toxin deployment in Laos, Cambodia, and Afghanistan as “yellow rain,” 7, 25, 356, 545
  - tularemia outbreak during World War II, 170
  - tularemia vaccine, 176, 471
  - use of *B mallei* as a biowarfare agent against Afghanistan, 122
  - voluntary anthrax vaccination program, 52
  - weaponization of monkeypox virus, 216
  - weaponization of viral hemorrhagic fevers, 276
  - WHO smallpox eradication program and, 9
  - Former Yugoslavia
    - Marburg virus and, 275
    - smallpox outbreak, 40–41
  - Fort Detrick, MD
    - aerial view (figure), 567
    - biological warfare research, 5–6, 122
    - biosafety evolution and, 516
    - clinical features of eight U.S. laboratory-acquired *B mallei* infections (table), 132–133
    - laboratory-acquired glanders infections, 125–126, 128, 131–132, 135–138
    - “Operation Whitecoat” use of volunteer soldiers to test vaccines, 6, 565–567
    - redirection of the biological weapons program, 8, 123
    - standard liquid biowaste disposal process, 530
    - U.S. Army Medical Unit under Col. William Tigertt (figure), 567
  - Fort Morgan virus. *See* Western equine encephalitis
  - Foshay, L.
    - tularemia vaccine research, 171
  - France
    - tularemia outbreaks, 170
  - Francis, Edward
    - tularemia research, 168, 170
  - French Indochina War
    - meliodosis and, 150
  - Fungi. *See* Trichothecene mycotoxins
- G**
- Gabon
    - Ebola viruses and, 275, 276
  - Gamma bacteriophage lysis
    - anthrax diagnosis, 77, 78
  - Gas-liquid chromatography
    - trichothecene mycotoxins, 363–364
  - Gastrointestinal anthrax
    - clinical disease, 76–77, 582–583
    - diagnosis, 78
    - mortality rate, 583
    - symptoms, 78
    - treatment, 79
  - Gelman, K. Ya.
    - mallein test development, 139
  - Genetic engineering
    - creation of biological threats, 595–596
    - laws restricting accidental or intentional creation of new deadly organisms, 596
    - recovering hazardous viruses from DNA clones, 596
  - Geneva Convention
    - response to biowarfare, 3
    - signatories, 3
    - United States delayed ratification of, 7
  - Gentamicin
    - anthrax treatment, 79
    - plague treatment, 111
    - tularemia treatment, 175
  - Germany
    - biowarfare during World War I, 3, 45–46, 122, 544
    - botulinum toxin development for use as a biological weapon, 339
    - Colorado potato beetle outbreaks during World War II and, 27
    - Lassa fever and, 273
    - Marburg virus and, 275
    - World War II field trials of foot and mouth disease dissemination, 28
  - Getty, B.
    - cowpox research, 225
  - Giardia lamblia*
    - swimming pools and, 27
  - Giardiasis
    - purposeful outbreak of in Scotland, 25
  - Gibb, T.R.
    - Ebola virus research, 407
  - Gilmore panel
    - recognition of covert attacks, 426
  - Glanders. *See also B mallei*
    - aerosol transmission, 125, 131, 135, 142
    - antibiotic resistance, 139
    - antibiotic therapy, 139–142
    - biowarfare potential, 122–124, 141–142
    - chronic disease, 128, 130, 134
    - clinical course, 130
    - clinical disease in animals, 128–130, 474
    - clinical disease in humans, 130–135, 474
    - clinical features of eight U.S. laboratory-acquired *B mallei* infections (table), 132–133
    - cutaneous manifestations, 130–131
    - decontamination procedures for patients, 141
    - description, 122, 474
    - diagnosis, 134–139, 142
    - differential diagnosis, 135
    - disease progression, 122
    - epidemiology, 125–126
    - equine glanders (and farcy) in Great Britain: 1877–1928 (figure), 124
    - eradication programs, 122–124, 135, 141–142
    - foreign animal disease designation in the United States, 138, 141
    - former Soviet Union use of as a biological weapon, 8
    - future research needs, 142
    - gene sequencing, 137, 142
    - German use of infected animals during World War I, 3, 45–46, 122
    - growth and morphology, 135–136
    - historical background, 123–124
    - human-to-human transmission, 126–127, 141
    - imaging studies, 134, 137, 140
    - incubation period, 128, 474
    - infectious agent, 124–125
    - isolation of the organism, 136
    - laboratory-acquired infections in the United States, 125–126, 128, 131, 135–138
    - laboratory safety issues, 127, 138, 141
    - latent period, 131–132, 134–135
    - lymphatic manifestations, 131, 135
    - mallein testing, 137–138
    - military relevance, 122–123
    - mortality rates, 130, 134
    - naturally infected species, 122
    - notification of local animal health authorities, 135, 141
    - organism identification, 123, 137, 142

pathogenesis, 127–128  
pathology, 122  
prophylaxis, 123, 140–141, 474–475  
septicemia and, 129–130, 133–134  
serology, 137  
Strauss reaction, 136  
symptoms, 122–123, 128–131, 474  
transmission, 126–127, 474  
treatment, 123, 135, 139–140, 474–475  
vaccines for, 123, 140, 474  
year equine glanders was last reported to OIE before 1996 (exhibit), 125

GLC. *See* Gas-liquid chromatography

Gleevac

smallpox and monkeypox treatment, 232–233

Glucocorticosteroids

trichothecene mycotoxins exposure treatment, 365

Goats

brucellosis and, 186

Q fever and, 201, 203, 206

Gonyautoxins. *See* Paralytic shellfish poisoning

Gram's stains

anthrax diagnosis, 77

glanders diagnosis, 135–136

tularemia diagnosis, 168

Great Britain. *See* United Kingdom

Green, Dr. Debra

poisoning of her estranged husband with ricin, 15

Grimm, V.

antibiotic susceptibility test research, 398

Grunow, R.

epidemiological assessment tool, 56–58

Guanarito virus

description, 274

*The Guide*. *See* *Guide for Care and Use of Laboratory Animals*

*Guide for Care and Use of Laboratory Animals*

federal regulations, 536

room fittings and ventilation for ABSL-3 facilities, 528

*Guidelines for Research Involving Recombinant DNA Molecules*

biosafety level terminology, 516

biosafety risk group assignments, 517

## H

Haffkine, Waldemar M.W.

plague vaccine development, 112

Haiti

castor bean cultivation, 324

Hannibal

serpent toxins and, 2

Hantaan virus

description, 275

Hantavax

viral hemorrhagic fever vaccine, 492

Hantavirus pulmonary syndrome

description, 274

Hantaviruses

clinical manifestations, 274–275, 279–280

geographic distribution, 274

hantavirus pulmonary syndrome, 274

Korean hemorrhagic fever, 275

poor sanitary conditions and, 274–275

Puumala virus, 275

Seoul virus, 275

Sin Nombre virus, 42, 275

treatment, 493

vaccine for, 290

Harris, Larry Wayne

arrest for possessing *Y. pestis*, 545–546

threatened use of anthrax to attack Las Vegas, 11–12

HE-BAT. *See* Botulinum antitoxin, heptavalent, equine  
Health Canada

biosafety risk group assignments, 518

Health Insurance Portability and Accountability Act  
National Laboratory Response Network and, 522

Heard, J.

ricin research, 327–328

Hemolytic uremic syndrome

*E. coli* O157:H7 and, 23–24, 584

Hemorrhagic fever with renal syndrome

description, 275

pathogenesis, 279–280

ribavirin treatment, 293, 493

Hendra virus

description, 591

outbreaks of, 591

HEPA filters. *See* High-efficiency particulate air filters

Heparin

viral hemorrhagic fever treatment, 289

Hepatitis

Q fever and, 203

Hepatitis A virus

drinking water and, 25

symptoms, 24

transmission, 24–25

vaccination program, 25

Herbicides

use in war, 27

Herpes B virus

treatment, 519

Heydrich, Reinhard

Czechoslovakia's use of botulinum toxin to assassinate, 4

Hfab-BAT. *See* Botulinum antitoxin F(ab')

HFRS. *See* Hemorrhagic fever with renal syndrome

High-efficiency particulate air filters

animal biological safety level 3 and level 4 facilities and, 525,  
528–529

biological safety cabinets and, 524

composition of, 517

development of, 517

efficiency of, 517

mechanisms of collection, 517

High-performance liquid chromatography

amnesic shellfish poisoning diagnosis, 372

neurotoxic shellfish poisoning diagnosis, 370

paralytic shellfish poisoning diagnosis, 368

trichothecene mycotoxins, 363–364

Highlands J virus. *See* Western equine encephalitis

Hilleman, Maurice

identification of adenoviruses and creation of vaccines against  
them, 565

HIPAA. *See* Health Insurance Portability and Accountability Act

Historical background

*Alphavirus* encephalitis, 243–244

anthrax, 70–71

biocrimes, 15

biodefense, ethics, and research in the 20th century, 562–569

biodefense and ethics in the 18th and 19th centuries, 561–562

biological terrorism, 11–16, 544–546

biosafety, 516–517

brucellosis, 186

cholera, 580–581

clostridial toxins, 373–374

disarmament, 7–8

early attempts at biowarfare, 2–3

- glanders, 123–124  
Iraq's biowarfare program, 10–11  
marine algal toxins, 365–366  
*Orthopoxvirus*, 2–3, 216, 220  
Q fever, 200  
ricin, 324–325  
smallpox vaccination, 227–229  
South African Defense Force, 10  
Soviet biowarfare program, 8–10  
trichothecene mycotoxins, 356–357  
U.S. biowarfare program, 5–6  
viral hemorrhagic fevers, 272–277  
World War I and World War II biowarfare programs, 3–5, 15
- HIV / AIDS  
emergence of, 597  
human behavior and spread of, 595  
opportunistic infections and, 597  
zoonotic origins, 580
- Homeland Security Act of 2002  
provisions, 417  
Strategic National Stockpile, 432
- Hong Kong  
H5N1 influenza virus and, 590  
severe acute respiratory syndrome and, 590
- Hoover, J. Edgar  
water supply vulnerability, 26–27
- Horses  
*Alphavirus* encephalitis and, 242–259  
glanders and, 122, 125–126, 128–130, 474  
Hendra virus and, 591
- Hospitals  
ancillary care centers and, 430–431  
antibiotic resistant diseases and, 587  
cohorting of patients, 429–430  
conventional and potential infectious diseases: required  
hospital infection control precautions (table), 455  
expanding surge capacity, 429–431  
Health Resources and Services Administration benchmarks for  
hospitals in the National Bioterrorism Hospital Preparedness  
Program, 429  
infection control, 428–429, 455–456  
isolation wards, 429  
Legionnaire's disease and, 582  
medical cache levels for local hospitals (exhibit), 432  
patient transfers, 429  
prehospital transport, 427–428  
transmission-based precautions, 429, 455–456  
triage issues, 428
- Howe, C.  
glanders research, 122, 126, 131
- HPLC. *See* High-performance liquid chromatography
- HPS. *See* Hantavirus pulmonary syndrome
- Hughes, M.L.  
brucellosis research, 186
- Human granulocytic ehrlichiosis. *See* Ehrlichiosis
- Hunter, S.E.  
clostridial toxin research, 376
- Hydroxychloroquine  
Q fever treatment, 205
- I**
- Iliukhim, V.I.  
melioidosis research, 158
- Illinois  
milk-borne *S typhimurium* outbreak, 23
- Imipenem  
anthrax treatment, 79  
glanders treatment, 140  
melioidosis treatment, 157, 159
- Immune globulin. *See also* Botulism immune globulin  
Kawasaki's syndrome treatment, 318  
ricin and, 331  
staphylococcal enterotoxin B treatment, 314, 318  
toxic shock syndrome treatment, 314
- Immunoassays. *See also* Enzyme-linked immunosorbent assay  
neurotoxic shellfish poisoning diagnosis, 370  
ricin, 330–331  
staphylococcal enterotoxin B, 318  
trichothecene mycotoxin detection kits, 363
- Immunodiagnostic methods  
biological agent detection and identification, 398–402  
comparison of methods (table), 400  
electrochemiluminescence, 400–401  
enzyme-linked immunosorbent assay, 79–80, 137–139, 190, 192,  
204, 226, 343, 399–400  
flow cytometry, 401–402  
heterogeneous assays, 399  
homogeneous assays, 399  
lateral flow assays, 402–403  
sensitivities, 398  
Standard Sandwich Immunoassay (figure), 399  
steps in, 399  
time-resolved fluorescence, 401
- Immunofluorescence assays  
smallpox, 226
- Immunosuppression  
smallpox and, 220, 223–224, 228–230, 449, 483, 488
- IMP dehydrogenase inhibitors  
viral hemorrhagic fever treatment, 494
- India  
brucellosis and, 187  
castor bean cultivation, 324  
early smallpox vaccination program, 227  
Kysanur forest disease, 276  
paralytic shellfish poisoning and, 367
- Indiana  
milk-borne *S typhimurium* outbreak, 23
- INDs. *See* Investigational New Drugs
- Infants and children  
anthrax treatment, 79, 470  
botulism and, 343, 497  
brucellosis treatment, 191  
*C jejuni* and, 23, 583–584  
*Cryptosporidium* and, 24  
dengue hemorrhagic fever / dengue shock syndrome and, 276  
*E coli* 0157:H7 and, 23–24, 584  
eastern equine encephalitis and, 253  
laboratory tests for plague, 111  
*Listeria monocytogenes* and, 23  
monkeypox and, 225  
paralytic shellfish poisoning and, 368  
plague meningitis and, 107  
plague treatment, 111–112  
routine vaccination against smallpox, 482  
*Shigella* infection and, 24  
smallpox and, 224  
smallpox vaccination and, 230–231, 483  
tularemia treatment, 175  
Venezuelan equine encephalitis and, 242  
western equine encephalitis and, 253–254
- Influenza  
antigenic drift and antigenic shift, 588  
avian influenza, 589–590  
description, 587

- emergency hospital during the 1918 pandemic (figure), 588
  - HA and NA subtypes, 587–589
  - historical background, 437, 587
  - H5N1 subtype, 590
  - H7N7 subtype, 589–590
  - impact of the pandemic on U.S. life expectancy, 588–589
  - influenza wards, U.S. Army camp hospitals (figure), 589
  - mortality rate, 588
  - negative-stained transmission electron micrograph showing the reconstructed 1918 influenza virions (figure), 588
  - overwhelming of the healthcare infrastructure, 429
  - poultry reservoirs, 589
  - reconstruction of the 1918 pandemic virus, 589
  - strains that cause pandemics, 587
  - swine influenza, 589
  - use of dentists as physicians during pandemics, 437
  - Informed consent
    - DoD deployments and, 571–572
    - English translation of the yellow fever informed consent document (figure), 563
    - historical background, 562–569
    - Investigational New Drugs, 570
    - Operation Whitecoat and, 565–567
    - Spanish translation of the yellow fever informed consent document (figure), 564
  - Inhalational anthrax
    - chest radiographic examination, 75, 78, 80
    - clinical disease characteristics, 75–76
    - computed tomography imaging, 78
    - diagnosis, 78, 80
    - mailings of letters contaminated with, 11, 13, 16, 50–51, 57, 76, 433, 460, 545–546, 583
    - meningitis and, 76, 80
    - mortality rate, 76
    - occupational causes, 70, 72, 79
    - rarity of, 72
    - symptoms, 75, 78, 80
    - treatment, 78–80
  - Institute of Medicine
    - definition of emerging infectious diseases, 580
  - Insurrection Act
    - military involvement in law enforcement and, 437
  - Interferon
    - viral hemorrhagic fever treatment, 494
  - International Animal Health Code
    - glanders and, 141
  - International Organization for Standardization
    - bioforensic standards, 406
  - Investigational New Drugs
    - animal efficacy rule and, 571, 574
    - authorization for research only, 570
    - BioShield emergency use authorization, 571
    - continuous data collection, 570
    - DoD deployments and, 571–572
    - informed consent and, 570–573
    - instituting waiver of informed consent for using, 573
    - military options for fulfilling mission and ethical responsibilities to military personnel, 572–573
    - recordkeeping requirements, 570
    - vaccine status and, 570–571
    - war situations and, 570–571
  - Iowa
    - milk-borne *S typhimurium* outbreak, 23
  - Iran
    - brucellosis and, 187
  - Iraq
    - biological warfare program, 10–11, 25, 545
    - botulinum toxin development for use as a biological weapon, 339
    - camelpox research, 221
    - Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction and, 545
    - ricin as a biological weapon and, 325
  - Ishii, Lt. Col. Shiro
    - amnesty after World War II, 5
    - botulinum toxin experimentation, 338
    - human research on Chinese nationals, 3–4, 338
    - use of plague as a biological weapon and, 95–96
  - Isolation of patients
    - biological agent attacks and, 427
    - definition, 427
    - plague and, 111, 113
    - viral hemorrhagic fevers and, 290
  - Italy
    - Legionella pneumophila* contamination in household hot water systems, 582
    - tularemia and, 169
  - Ivory Coast
    - Ebola viruses and, 275
  - Ivy, Dr. Andrew
    - Nuremberg Code and, 565
- ## J
- Jackson, R.J.
    - virulence of orthopoxviruses, 405
  - Japan
    - amnesic shellfish poisoning and, 371
    - attempt to obtain yellow fever virus strains from Rockefeller University, 562
    - Aum Shinrikyo cult's sarin attack in the Tokyo subway, 12, 339, 427, 545
    - Aum Shinrikyo cult's use of anthrax and botulinum toxin in attacks, 12, 16, 22, 48–49, 407, 545
    - botulinum toxin development for use as a biological weapon, 339
    - chemical warfare experiments, 4
    - development of *B mallei* as a biowarfare agent in World War II, 122
    - development of biological weapons for sabotage operations, 3–4
    - experimentation with *F tularensis* as a biological weapon, 168
    - "field trials" of biological agents, 4, 6–7
    - Korean hemorrhagic fever and, 275
    - Lassa fever and, 273
    - melioidosis and, 149–150, 156
    - paralytic shellfish poisoning and, 367
    - poisoning of wells with *S typhimurium* during World War II, 23
    - "red mold disease" of wheat and barley, 357
    - Suzuki's contamination of food items with *Salmonella typhi* and agents of dysentery, 15
    - trichothecene mycotoxins and, 357
    - use of biowarfare against China during World War II, 3–4, 220, 544
    - use of plague as a biological weapon and, 95–96
    - use of smallpox as a biological weapon against China, 220
    - vaccine research, 4
  - JBAIDS. *See* Joint Biological Agent Identification and Diagnostic System
  - Jenner, Edward
    - smallpox vaccine research, 227–228, 482
  - Jewett, Frank B.
    - Japan's attempt to obtain yellow fever virus strains from Rockefeller University and, 562

JFO. *See* Joint Field Offices  
 Joint Biological Agent Identification and Diagnostic System  
   description, 392  
   development of, 407–408  
 Joint Biological Point Detection System  
   description, 446  
 Joint Commission on Accreditation of Healthcare Organizations  
   laboratory safety audits, 534  
 Joint field offices  
   description, 419  
   organizational structure (figure), 419  
 Jordan  
   brucellosis and, 187  
 Junin virus  
   isolation of, 274  
   transmission electron micrograph (figure), 277  
   vaccine for, 290  
   weaponization of, 274  
 Justinian plague  
   description, 92

## K

Kansas  
   ehrlichiosis and, 586  
 Kawasaki's syndrome  
   causative organisms, 313  
   treatment, 318  
 Keim, P.  
   *B anthracis* research, 406–407  
 Kempe, C.H.  
   vaccinia immune globulin research, 491  
 Kenya  
   Mau-Mau insurgency use of indigenous poisonous African  
   milk bush to kill cows, 27  
 Kirby-Bauer disk diffusion  
   antibiotic susceptibility test, 398  
 Koch, Robert  
   anthrax research, 70, 72  
   *C perfringens* research, 373  
   plague research, 92  
 Korea  
   amnesic shellfish poisoning and, 371  
 Korean hemorrhagic fever  
   description, 275  
   disseminated intravascular coagulation and, 286  
 Korean War  
   allegations against the United States of using biological  
   warfare, 6–7, 96  
   hantaviruses and, 275  
 Korte, Amaas  
   smallpox research, 223  
 Kosovo  
   tularemia outbreak, 55–56, 168, 170  
 Kostov, Vladimir  
   ricin attack on, 9–10  
 Krishnaswami, Dr. C.S.  
   *B pseudomallei* isolation, 148  
 Kuwait  
   brucellosis and, 187  
 Kyasanur forest disease  
   biphasic course, 276  
   description, 276  
   geographic distribution, 276  
   vaccine for, 290

## L

Laboratory-acquired infections  
   brucellosis, 186  
   glanders, 125–126, 128, 131, 135–138  
   staphylococcal enterotoxin B, 317–318  
   tularemia, 170  
   Venezuelan equine encephalitis, 242  
   western equine encephalitis, 257  
 Laboratory animal care and use program  
   federal animal welfare regulations, 536  
 Laboratory identification of biological threats  
   antibiotic susceptibility testing, 398  
   bioforensics, 406–407  
   biosafety considerations, 394–395  
   biosecurity considerations, 395–397  
   bioterrorism incidents, 1984–2004 (table), 405  
   clinical microbiological methods, 397–398  
   comparison of immunodiagnostic methods (table), 400  
   diagnostic systems to detect multiple biological markers  
   (figure), 408  
   early recognition of host response, 407  
   emerging threats, 405–406  
   future approaches, 407–408  
   identification approaches, 397–405  
   immunodiagnostic methods, 398–402  
   Joint Biological Agent Identification and Diagnostic System,  
   407–408  
   key identity markers for selected biological select agents and  
   toxins (table), 396  
   laboratory response, 392–397  
   Laboratory Response Network, 392, 394  
   military field laboratories, 392, 394  
   molecular detection methods, 403–405  
   regulated biological select agents and toxins (exhibit), 393  
   role of military clinical and field laboratories, 392–397  
   specimen collection and processing, 397  
 Laboratory Response Network  
   bioforensic standards, 406  
   civilian LRNs, 394  
   clinical laboratories, 522  
   creation of, 522  
   guidelines for identifying the highest priority bioterrorism  
   agents, 397  
   laboratory descriptions (exhibit), 457  
   military LRNs, 394  
   national laboratories, 522  
   reference laboratories, 522  
   requests by local and regional health authorities for assistance,  
   457  
   role of laboratories, 394  
   sentinel laboratories, 395, 522  
 Laboratory safety audits  
   DoD RDTE facilities, 534–535  
   events that warrant unscheduled audits, 534  
   list of elements, 534  
   self-audits of required safety practices, 534  
   terminology, 533–534  
 Lamb, B.H.  
   tularemia research, 168  
 Laos  
   former Soviet Union's deployment of trichothecene toxins, 7,  
   25, 356, 545  
 Lassa fever virus  
   biosafety risk group assignment, 518  
   clinical manifestations, 279  
   deafness and, 273, 279  
   description, 273

- geographic distribution, 273
- mortality rate, 273
- passive immunotherapy, 494
- ribavirin treatment, 292, 493
- thrombocytopenia and, 285
- Lateral flow assays
  - advantages of, 402
  - assay format (figure), 403
  - description, 402
- League of Nations
  - Conference for the Supervision of the International Trade in Arms and Ammunition, 3
- Lee, L.G.
  - real-time polymerase chain reaction research, 404
- Legal issues. *See also* Ethical and legal dilemmas in biodefense research
  - altering the standard of medical care in a large-scale biological agent attack, 436–437
  - prohibition against military involvement in law enforcement, 437
  - protective clothing regulations, 436
  - quarantine compliance, 437
- Legionella*-like amoebal pathogens
  - description, 582
- Legionnaire's disease
  - clinical manifestations, 582
  - community-acquired, 582
  - description, 582
  - hospitals and, 582
  - mortality rate, 582
  - nonpneumonic type, 582
  - transmission, 582
- Legislation. *See also specific legislation*
  - biological attacks and, 416–417
  - Defense Against Weapons of Mass Destruction Act, 416–417
  - Emergencies Involving Chemical or Biological Weapons Act, 417
  - Homeland Security Act of 2002, 417
  - Stafford Act, 416
- Leitenberg, M.
  - biocrimes analysis, 15
- Lice
  - relapsing fevers caused by, 586
- Lister, Joseph
  - smallpox vaccination research, 227
- Listeria monocytogenes*
  - diseases caused by, 23
  - incubation period for illness from, 23
- Liu, Y.
  - botulinum toxin research, 339
- Livak, K.J.
  - real-time polymerase chain reaction research, 404
- Livestock. *See also* Cattle
  - agricultural terrorism and, 27–28
  - brucellosis and, 186
  - Q fever and, 201, 202
- LLAPs. *See* *Legionella*-like amoebal pathogens
- Local response to a biological attack
  - ancillary care centers, 430–431
  - cohorting of patients, 429–430
  - containment of disease, 424–427
  - covert release response, 426–428
  - decontamination of people exposed at the incident site, 425–426
  - decontamination technologies, 426
  - EMS responders and, 424–425, 427–428
  - expanding surge capacity, 429–431
  - flow diagram for a campaign responding to smallpox or other communicable agent (figure), 435
  - hospital infection control, 428–429
  - hospital triage, 428
  - incident scene zones, 424
  - initial response, 424
  - isolation and quarantine, 427
  - isolation wards, 429
  - local stockpiles of supplies and pharmaceuticals, 431–432
  - mass fatalities, 436
  - mass logistics, 431–433
  - mass patient care, 427–431
  - mass prophylaxis, 433–436
  - medical cache levels for local hospitals (exhibit), 432
  - prehospital transport, 427–428
  - prophylaxis distribution center flow diagram (figure), 434
  - recognition of covert attacks, 426–427
  - requesting assistance from the state, 456–457
  - response to an intentional biological agent flow diagram (figure), 425
  - Strategic National Stockpile, 13, 14, 421, 432–433, 459
  - suggested minimum staffing per 12-hour shift for a 50-bed nursing subunit (exhibit), 431
- Loeffler, F.
  - glanders research, 125, 127, 136, 140
- Los Angeles, CA
  - plague epidemic, 102
- LRN. *See* Laboratory Response Network
- Lyme disease
  - clinical manifestations, 585
  - darkfield photomicrograph of the Lyme disease spirochete (figure), 585
  - Ixodes scapularis* tick (figure), 585
  - tick vectors for, 585
- Lymphogranuloma venereum
  - plague differential diagnosis, 109–110

## M

- M-44 vaccine
  - Q fever, 206, 477–478
- M291 decontamination kit
  - trichothecene mycotoxins and, 364
- Machupo virus
  - isolation of, 274
  - weaponization of, 274
- Mack, T.M.
  - review of smallpox cases in Europe, 229
- Mad cow disease. *See* Bovine spongiform encephalitis
- Maitland, Charles
  - smallpox vaccination and, 227
- Malaria
  - viral hemorrhagic fever differential diagnosis, 287
- Malaysia
  - Nipah virus and, 591–592
- Mallein testing
  - glanders, 137–139
- Malleus. *See* Glanders
- Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, 138
- Marboran
  - smallpox treatment, 232
- Marburg virus
  - agent characteristics, 278
  - biosafety risk group assignment, 518
  - clinical manifestations, 280
  - description, 275
  - disseminated intravascular coagulation and, 280, 286
  - heparin treatment, 293

- laboratory workers and, 275
- mortality rate, 275
- petechial rash (figure), 280
- skin rash, 280, 285
- vaccine for, 292
- weaponization of, 274
- Mardani, M.
  - Crimean-Congo hemorrhagic fever research, 493
- Marennikova, S.S.
  - vaccinia immune globulin research, 491
- Marine algal toxins
  - amnesic shellfish poisoning, 366, 371–373
  - azaspiracid shellfish poisoning, 366
  - blooms and, 366, 367, 369, 371
  - ciguatera fish poisoning, 366
  - comparison of selected marine algal toxins (table), 367
  - diarrheic shellfish poisoning, 366
  - fish kills and, 365
  - global distribution, 365
  - historical background, 365–366
  - long-term environmental and public health effects, 365–366
  - neurotoxic shellfish poisoning, 366, 369–371
  - paralytic shellfish poisoning, 366–369
  - potential biowarfare or bioterrorism threat, 366
  - syndromes identified with, 366
  - V. vulnificus* infection, 581
- Markov, Georgi
  - assassination of with ricin, 9, 327–328
- Marr, J.S.
  - The Eleventh Plague*, 25
- Marshall, Lt. Col. John D.
  - plague research, 94
- Marston, J.A.
  - brucellosis research, 186
- Martin, D.B.
  - Orthopoxvirus* research, 219
- Maryland
  - anthrax and glanders events of 1915–1916 case study, 45–46
- Mass chromatography
  - neurotoxic shellfish poisoning, 370
- Mass fatalities
  - disposition of infected remains, 436
  - mortuary affairs, 436
- Mass logistics
  - local stockpiles, 431–432
  - Strategic National Stockpile, 432–433
- Mass patient care
  - prehospital transport, 427–428
- Mass prophylaxis
  - Bioterrorism and Epidemic Response Model, 433–434
  - flow diagram for a campaign responding to smallpox or other communicable agent (figure), 435
  - point of distribution and, 433–434, 436
  - prophylaxis distribution center flow diagram (figure), 434
  - push and pull systems for distribution, 433
  - uncommon antibiotics, antivirals, immunoglobulins, or vaccines and, 433
- Mass spectrometry
  - trichothecene mycotoxins, 363–364
- Mass spectrometry receptor-binding assays
  - neurotoxic shellfish poisoning diagnosis, 370
- Massachusetts
  - eastern equine encephalitis outbreak, 243
  - Listeria monocytogenes* epidemic, 23
  - Martha's Vineyard tularemia outbreak case study and lessons learned, 54–55, 170, 173
- Mather, Cotton
  - smallpox vaccination and, 227
- Mayaro virus. *See Alphavirus* encephalitis
- McCoy, G.W.
  - tularemia research, 168
- McDade, Joseph
  - Legionella pneumophila* discovery, 582
- Medical countermeasures against bioterrorism
  - alphaviruses, 478–481
  - anthrax, 467–471
  - bacterial and rickettsial diseases, 467–478
  - botulinum toxin, 495–497
  - brucellosis, 475–476
  - glanders, 474–475
  - melioidosis, 474–475
  - military troops and, 498
  - plague, 473–474
  - postexposure antibiotic prophylaxis regimens (table), 467
  - Q fever, 476–478
  - ricin, 498
  - risk-benefit assessments, 499
  - smallpox, 481–492
  - staphylococcal enterotoxin B, 497–498
  - toxins, 495–498
  - tularemia, 471–473
  - vaccination of civilians and, 499
  - vaccines, vaccine dosage schedules, and postvaccination protection (table), 466
  - viral hemorrhagic fevers, 492–495
  - virology, 478–495
- Medical Management of Biological Casualties Handbook*, 445–460
- Medical management of potential biological casualties
  - alerting the proper authorities, 456–457
  - AMPLE history and, 452
  - Biological Integrated Detection System, 445
  - biosafety levels (exhibit), 458
  - Chemical-Biological Incident Response Force, 458
  - Chemical/Biological Rapid Response Teams, 458
  - chemical protection, 447
  - conventional and potential infectious diseases: required
    - hospital infection control precautions (table), 455
  - critical agents for health preparedness (table), 447
  - disinfecting or decontaminating, 450–452
  - epidemiological investigation, 445–446, 459
  - the epidemiological sequence (exhibit), 459
  - establishing a diagnosis (the secondary assessment), 452
  - immunological protection, 447–450
  - incubation periods of biological agents and, 445, 450
  - Joint Biological Point Detection System, 446
  - Laboratory Response Network and, 457
  - local and regional health authorities and, 456–457
  - maintaining a healthy index of suspicion, 445–446
  - managing the psychological aftermath of a biological attack, 459
  - military support, 458–459
  - personnel training needs, 444
  - points of contact and training resources (exhibit), 457
  - Portal Shield Biological Warfare Agent Detection System, 445–446
  - protecting yourself, 446–450
  - providing prompt therapy, 452–455
  - public panic and, 459
  - recommended therapy for (and prophylaxis against) diseases
    - caused by category A biothreat agents (table), 453–454
  - risk communication plans and tactics, 459
  - samples to consider obtaining from potential biowarfare/bioterrorism victims (exhibit), 452
  - saving the patient's life (the primary assessment), 450

- Medical surveillance for laboratory personnel
  - ancillary studies, 526–527
  - baseline and periodic studies, 526
  - BSL-4 suit facilities, 527
  - objectives, 527
- Mediterranean fruit flies
  - release of in California, 27
- Melioidosis
  - animal models, 151
  - antibiotic resistance, 156
  - bacterial identification kits, 156
  - candidate virulence factors (exhibit), 151–153
  - clinical disease, 153–156
  - clinical manifestations, 148, 158, 474
  - description, 153, 474
  - diagnosis, 156, 158–159
  - emerging infectious disease designation, 148, 158
  - epidemiology, 150
  - former Soviet Union use of as a biological weapon, 8
  - human-to-human transmission, 153
  - imaging features (figures), 154–155
  - incubation period, 153, 474
  - infectious agent, 148–149
  - latent period, 150, 155–156
  - military relevance, 149–150
  - pathogenesis, 150–153
  - potential bioterrorism threat of, 148, 150, 158
  - prevention, 157–158
  - prophylaxis, 158–159
  - pulmonary type, 153, 474
  - radiographic findings (figure), 154
  - risk factors, 148, 153, 156, 158
  - septicemia and, 153–154, 158
  - skin lesions (figures), 155
  - treatment, 156–157, 159, 474–475
  - tropical and subtropical regions and, 148, 158
  - vaccines, 157–158
  - virulence factors, 150–153
- Menangle virus
  - description, 592
- Mendelson, R.W.
  - glanders research, 140
- Mendis, C.
  - staphylococcal enterotoxin B research, 407
- Meningitis
  - anthrax and, 76–78, 80
  - plague meningitis, 107
- Merck, George W., Jr.
  - biological warfare research, 5
  - War Research Service and, 562, 565
- Meropenem
  - glanders treatment, 140
  - melioidosis treatment, 157, 159
- Methylthiazolidine-4-carboxylate
  - trichothecene mycotoxins exposure treatment, 365
- Metoclopramide
  - trichothecene mycotoxins exposure treatment, 365
- Mexico
  - amnesic shellfish poisoning and, 371
  - brucellosis and, 187
  - Venezuelan equine encephalitis outbreaks, 243, 248
  - West Nile virus and, 594
- Meyer, Karl F.
  - plague vaccine development, 112
- Michigan
  - Department of Community Health responsibility for the formulation of pentavalent botulinum toxoid, 345, 495
  - milk-borne *S typhimurium* outbreak, 23
  - Q fever and, 202
- MICROCHEM PLUS
  - hospital disinfectant, 530
- Middle East. *See also specific countries*
  - brucellosis and, 187
  - glanders and, 122, 125
- Military field laboratories
  - Air Force, 394
  - Army, 392, 394
  - function, 392
  - microbiology augmentation sets, 392
  - Navy, 394
  - sentinel role, 392
- Military services
  - Armed Forces Medical Policy Council, 565
  - instituting waiver of informed consent for using INDs, 573
  - negotiating for accelerated licensure of INDs, 572
  - options for fulfilling mission and ethical responsibilities to military personnel, 572–573
  - relationship with the Food and Drug Administration, 560
  - respiratory disease research, 565
  - unethical research involving LSD on uninformed soldiers, 567
  - using INDs without full compliance, 572
  - vaccine development successes, 569
- Milk supply. *See also Dairy foods*
  - C botulinum* contamination potential, 22–23
  - Listeria monocytogenes* and, 23
  - potential for bioterrorist contamination, 29
  - Q fever and, 201
  - Salmonella* and, 23, 584
- Miller, W.R.
  - glanders research, 122, 126, 131
- Milwaukee, WI
  - Cryptosporidium* drinking-water outbreak, 24, 27
- Minnesota
  - antimicrobial-resistant salmonellosis outbreak, 29
  - gastrointestinal anthrax outbreak, 583
- Missouri
  - tularemia outbreaks, 169
- Miyamoto, O.
  - clostridial toxin treatment research, 376
- Modified Vaccinia Ankara vaccine
  - smallpox vaccination, 229, 449, 491
- Molecular detection methods
  - polymerase chain reaction, 110, 137, 156, 174–175, 190, 204–205, 255, 318, 343, 403
  - real-time PCR, 404
  - reverse transcriptase-PCR, 403–404
  - TIGER, 404–405
- Monkey disease. *See Kyasanur forest disease*
- Monkeypox
  - antiviral drug treatment, 231–233
  - clinical manifestations, 224
  - complications from, 224–225
  - infectious dose, 220
  - mortality rates, 220, 225
  - potential for use in biowarfare, 220
  - sine eruption* form, 224
  - transmission, 220
  - treatment, 231–233
  - vaccine for, 217, 225
  - weaponization of by the former Soviet Union, 216
- Monovalent vaccine
  - botulinum toxin treatment candidate, 346
- Montagu, Lady Mary Wortley
  - smallpox vaccination and, 227

- Montana  
*Borrelia*-caused outbreaks, 586  
 Q fever and, 200, 205
- Morphine injector's septicemia. *See* Melioidosis
- Mosquitos  
*Alphavirus* encephalitis and, 242, 244, 246–248, 253  
*Bunyaviridae* and, 274  
*Flaviviridae* and, 276, 592–594  
 viral hemorrhagic fevers and, 287
- Mouse bioassay  
 paralytic shellfish poisoning diagnosis, 368
- MS. *See* Mass spectrometry
- Mules  
 glanders and, 122, 126, 128–130
- Mullis, Kary  
 polymerase chain reaction research, 403
- MVA. *See* Modified Vaccinia Ankara vaccine
- Mycotoxins. *See also* Trichothecene mycotoxins  
 bioterrorism potential, 25  
 fusarium mycotoxin association with esophageal cancer, 25  
 hygiene measures and, 25  
 symptoms of mycotoxicosis, 25  
 trichothecene intoxications, 25
- Myopericarditis  
 histopathology of (figure), 490  
 smallpox vaccination complication, 228, 448, 490
- N**
- Naloxone  
 trichothecene mycotoxins exposure treatment, 365
- National Academy of Sciences  
 offensive use of trichothecene mycotoxins, 357  
 report on *C botulinum* contamination potential, 22–23
- National Cancer Institute  
 biosafety cabinets, 517
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
 Belmont Report and, 567–569  
 creation of, 567–568
- National Drug Company  
 live attenuated tularemia vaccine, 472  
 TC-83 vaccine manufacture, 478
- National Electronic Disease Surveillance System  
 anthrax mailing investigation and, 50  
 description, 522
- National Incident Management System  
 description, 417  
 requests by local and regional health authorities for assistance from the state, 456–457
- National Institute for Occupational Safety and Health  
 protective clothing recommendations, 425  
 respirator systems, 525, 526
- National Institute of Allergy and Infectious Diseases  
 coordination of civilian medical countermeasure development, 14  
 National Biosafety and Biocontainment Training Program, 537
- National Institutes of Health  
*Guidelines for Research Involving Recombinant DNA Molecules*, 516
- National laboratories  
 description, 522
- National Research Act  
 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 567–568
- National Research Council  
 offensive use of trichothecene mycotoxins, 357
- National Response Plan  
 base plan and emergency support functions, 417–418  
 Biological Incident Annex, 420–421  
 concept of operations, 418–420  
 defense coordinating officer, 419–420  
 defense support to civilian authorities, 420  
 development of, 13  
 elements of an effective biological response, 421  
 emergency support functions (table), 418  
 federal response and support to state and local jurisdictions and, 457–458  
 integration of previously existing plans, 417  
 joint field office, 419  
 National Incident Management System, 417, 456–457  
 situations covered by, 417  
 Strategic National Stockpile and, 421
- National response to a biological attack  
 Biological Incident Annex, 420–421  
 Chemical and Biological Incident Response Force, 422  
 Defense Department bioterrorism response assets, 421–424  
 defense support to civilian authorities, 420  
 legislation, 416–417  
 National Response Plan, 417–420  
 20th Support Command, 422  
 U.S. Army Medical Research Institute of Infectious Disease's patient-containment care suite, 423–424  
 US Northern Command and, 422  
 Weapons of Mass Destruction Civil Support Teams, 422
- National Security Council  
 Weapons of Mass Destruction Medical Countermeasures Subcommittee, 14
- Native Americans  
 infection of Native Americans with smallpox, 2–3, 220, 544
- Naval Medical Research Center  
 identifying and confirming the presence of biological threats, 392  
 Laboratory Response Network responsibilities, 394
- NDBR 101 vaccine  
 adverse events, 473  
 "take" from (figure), 472–473  
 tularemia and, 472
- NDBR 105 vaccine  
 Q fever, 477
- Neff, J.M.  
 vaccinia research, 489
- The Netherlands  
 Lassa fever and, 273
- Neurotoxic shellfish poisoning  
 anti-brevetoxin IgG treatment, 371  
 causative agent, 366  
 clinical manifestations, 369–370, 377  
 diagnosis, 370  
 ingestion route, 369–370  
 inhalation route, 370  
 mechanism of action, 369, 377  
 medical management, 370–371  
 potential biowarfare or bioterrorism threat, 371  
 supportive care, 370, 377  
 toxic dose, 370  
 toxin description, 369  
 treatment, 370–371, 377
- New Jersey  
 eastern equine encephalitis and, 242  
 ehrlichiosis and, 586
- New Mexico  
 plague epidemics, 102, 105–106, 110
- New York City  
 anthrax and glanders events of 1915–1916 case study, 45–46

- open-air tests of pathogens in subways, 6
- public health department surveillance system, 60
- West Nile virus outbreak, 41–42, 53–54, 594
- New Zealand
  - amnesic shellfish poisoning and, 371
  - neurotoxic shellfish poisoning and, 369
- NIH Guidelines. *See Guidelines for Research Involving Recombinant DNA Molecules*
- Nimodipine
  - amnesic shellfish poisoning treatment, 373
- NIMS. *See National Incident Management System*
- NIOSH. *See National Institute for Occupational Safety and Health*
- Nipah virus
  - bats and, 591–592
  - clinical manifestations, 591
  - flying foxes as the natural reservoir for (figure), 592
  - molecular studies, 591
- Nixon, Pres. Richard
  - ban on offensive toxin weapons, 312, 338, 545
- Noncompetitive N-methyl-D-aspartate receptor antagonists
  - amnesic shellfish poisoning treatment, 373
- North America. *See also specific countries*
  - dengue fever and, 276, 593
  - Lyme disease and, 585
  - paralytic shellfish poisoning and, 367
  - plague incidence, 101
  - tularemia and, 168, 170
  - Venezuelan equine encephalitis and, 244, 248
- North Korea
  - allegations against the United States of using biological warfare during the Korean War, 6–7
  - yellow fever weaponization, 276
- NORTHCOM. *See U.S. Northern Command*
- NSF International Standard / American National Standard for Biosafety Cabinetry
  - biological safety cabinet certification, 524
- NSP. *See Neurotoxic shellfish poisoning*
- Nuclear magnetic resonance spectrometry
  - trichothecene mycotoxins, 363
- Nunn-Lugar-Domenici Act. *See Defense Against Weapons of Mass Destruction Act*
- Nuremberg Code
  - conditions required for research involving human subjects, 565
  - text (figure), 566
- Nuttall, George
  - C. perfringens* research, 373

## O

- Occupational Safety and Health Administration
  - anthrax treatment recommendations, 470
  - first-receiver guidance for employees outside the hospital decontamination zone, 428
  - “Hazardous Waste and Operations and Emergency Response,” 424
  - protective clothing for employees in the hospital decontamination zone, 428
  - protective clothing regulations, 436
  - Respiratory Protection Standard, 525–526
- Office International des Epizooties
  - glanders and, 124, 138
  - Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, 138
- Ofloxacin
  - brucellosis treatment, 476
  - glanders treatment, 140
  - melioidosis treatment, 157
- OIE. *See Office International des Epizooties*

- Oklahoma
  - tularemia outbreaks, 169
- Olsnes, S.
  - ricin research, 324
- Omsk hemorrhagic fever
  - biphasic course, 276
  - description, 276
  - geographic distribution, 276
- O’nyong-nyong virus. *See Alphavirus encephalitis*
- Operation Desert Shield / Desert Storm
  - Iraq’s use of biological weapons and, 10–11
  - pyridostigmine bromide as preexposure prophylaxis against soman intoxication, 447
- Operation Whitecoat
  - informed consent form (figure), 568
  - model for the conduct of biodefense research involving human subjects, 565–567
  - Q fever research, 567
  - tularemia research, 567
  - use of volunteer soldiers to test vaccines, 6, 565–567
- Oregon
  - amnesic shellfish poisoning and, 371
  - salmonellosis outbreak in The Dalles, 23, 46–48, 545, 584
- Oropharyngeal anthrax
  - clinical disease, 76–77, 583
  - diagnosis, 78
  - treatment, 79
- Orthopoxvirus. *See also Buffalopox; Camelpox; Cowpox; Monkeypox; Smallpox*
  - classification, 216
  - clinical aspects of infections, 221–225
  - clinical manifestations, 219
  - cytoplasmic inclusion bodies in cells infected with (figure), 218
  - diagnosis, 225–227
  - disease course, 219
  - genetic engineering and, 221
  - historical background, 2–3, 216, 220
  - morphology, 216
  - pathogenesis, 219–220
  - phylogenetic relationships, 217–218
  - potential for use as a biowarfare or bioterrorism threat, 220–221, 228
  - poxviruses that cause human disease (table), 217
  - replication, 218–219
  - septic shock and, 220, 233
  - skin lesions, 219
  - transmission, 219
  - transmission electron micrograph of (figure), 216
  - virulence factors, 220–221, 405
- Oyston, P.C.
  - clostridial toxin research, 376

## P

- Pakistan
  - Crimean-Congo hemorrhagic fever and, 274
- Panama
  - Venezuelan equine encephalitis and, 246–247
- PAPRs. *See Powered air-purifying respirators*
- Paralytic shellfish poisoning
  - anti-STX serum and antibodies as antidotes, 369, 377
  - causative agent, 366, 377
  - cause of death, 368
  - clinical manifestations, 367–368
  - diagnosis, 368
  - ingestion route, 367–368
  - inhalation route, 368
  - lethal dose, 368

- mechanism of action, 367, 377
- medical management, 368–369, 377
- mortality rate, 367
- potential biowarfare or bioterrorism threat, 369
- supportive care, 368
- toxin description, 366–367
- Parasites
  - bioterrorism potential, 25
- Pasteur, Louis
  - anthrax research, 72
  - anthrax vaccine development, 70
- Patient-containment care suites
  - description, 423
  - limitation of, 423–424
- Patriot Act
  - Select Agent Program and, 535
- PBT. *See* Pentavalent botulinum toxoid
- PCR. *See* Polymerase chain reaction
- PE-6 vaccine
  - eastern equine encephalitis and, 258
  - western equine encephalitis and, 258
- Pearson, T.
  - B anthracis* research, 407
- Penicillin
  - anthrax treatment, 78
- Pennsylvania
  - Emergency Preparedness Resource Inventory software, 431–432
- Pentavalent botulinum toxoid
  - adverse events, 345, 496
  - at-risk laboratory workers and, 495
  - availability of, 495
  - botulism vaccine, 345, 495–496
  - description, 495
  - dosing schedule, 345, 496
  - preexposure prophylaxis, 345–346
- Persian Gulf War
  - DoD use of botulism vaccine, 571
  - emerging infectious disease threats and, 405
  - field laboratories and, 392
  - “Gulf War syndrome” and, 571
  - pentavalent botulinum toxoid potency vaccination of service members, 345
  - Q fever and, 201
  - use of biological agents and, 338
- Personal protective equipment
  - animal housing and, 525
  - disposable clothing, 525
  - enforcement of rules for, 525
  - hospital decontamination zone and, 428
  - on-scene responders to biological attacks, 424–425, 446–447
  - overboots, 526
  - patient-containment care suite and, 423
  - protective gloves, 525–526
  - respirator systems, 525–526
  - risk mitigation and, 524
  - training in use of, 527
  - trichothecene mycotoxins and, 364
- Peru
  - brucellosis and, 187
  - Venezuelan equine encephalitis and, 243
- Pharyngeal plague
  - clinical manifestations, 108
- Philippine hemorrhagic fever
  - description, 276
- Phosphodiesterases
  - staphylococcal enterotoxin B treatment, 314
- Pihl, A.
  - ricin research, 324
- Pike, R.M.
  - laboratory-acquired infection research, 551
- Pine Bluff, AR
  - biological warfare research and production, 5
  - conversion to a research facility, 8
- Pittman, P.R.
  - CM4884 vaccine research, 480
- Plague. *See also* *Y pestis*
  - absence of buboes and, 105, 110
  - antibiotic resistance, 112
  - antibiotic treatment, 111–112
  - biochemistry, 97–98
  - biovar *antiqua*, 97–98
  - biovar *mediaevalis*, 98
  - biovar *orientalis*, 97
  - bubo examples (figures), 106
  - bubonic plague, 92, 105, 113
  - cervical lymphadenopathy, 92
  - climatic variables, 101
  - clinical manifestations, 105–108, 445
  - cutaneous manifestations, 108
  - cyclic transmission between rodents and fleas, 102
  - “dance of death” description, 93
  - description, 92, 473
  - diagnosis, 109–111, 113
  - differential diagnoses, 109–110
  - endemic disease, 94–95
  - enzootic cycle, 101
  - epidemiology, 98–101
  - epizootic cycle, 101–102
  - F1 capsular antigen and, 103–104, 110, 474
  - flea vectors, 98, 100–101, 113
  - flea virulence factors, 104
  - former Soviet Union use of as a biological weapon, 8
  - global distribution (figure), 102
  - growth characteristics, 97
  - handling corpses infected with, 436
  - historical background, 92–94
  - human-to-human transmission, 101
  - incidence, 101–102
  - incubation phase, 105
  - infectious agent, 96–98
  - isolation of patients, 111, 113
  - known mammalian reservoirs of plague in the United States (figure), 99
  - laboratory tests, 110–111
  - low calcium response and, 103
  - mammals known to harbor (exhibit), 100
  - mass casualty treatment, 112
  - meningitis, 107
  - military campaigns and, 92
  - morphology, 97
  - mortality rate, 105
  - most likely biological warfare scenario, 113
  - new vaccine research, 474
  - oriental rat flea (figure), 98
  - pandemics, 92–94
  - pathogenesis, 104–105
  - PH 6 antigen, 104
  - pharyngeal, 108
  - plague cycles in the United States (figure), 100
  - plague meningitis, 107
  - plague risks at U.S. military installations (table), 95
  - plasminogen activator, 104
  - pneumonic plague, 92, 105, 107–108, 110, 113

- postexposure prophylaxis, 112, 474
  - potential use as a biological warfare agent, 95–96, 473
  - prevention measures, 112
  - rats and, 98–101
  - septicemic plague, 92, 105, 107–108, 110, 113
  - signs and symptoms, 109–110
  - taxonomy, 96–97
  - transmission, 92, 473
  - treatment, 111–113, 474
  - type III secretion system, 103
  - U.S. military installations and, 94–95
  - use of plague victims in early warfare, 2, 95, 544
  - vaccination for, 92, 94, 112–113, 450, 473–474
  - virulence determinants, 102–104, 474
  - Wright-Giemsa stain for (figure), 97
  - Pneumonic plague
    - chest roentgenography, 107–108
    - clinical manifestations, 107
    - cutaneous manifestations, 108
    - differential diagnosis, 110
    - hospital infection control precautions, 429
    - military relevance of the primary form, 92
    - mortality rate, 92
    - primary type, 92, 107
    - secondary type, 92, 105, 107
    - transmission-based precautions, 455
    - transmission route, 105
    - treatment, 107
  - Poland
    - pseudoepidemics of typhus during World War II, 4
  - Poli, M.A.
    - Recent Advances in Marine Biotechnology, Volume 7: Seafood Safety and Human Health*, 369
  - Polymerase chain reaction. *See also* Real-time polymerase chain reaction; Reverse transcriptase polymerase chain reaction
    - Alphavirus* encephalitis, 255
    - botulinum toxin, 343
    - brucellosis, 190
    - description, 403
    - glanders, 137
    - meliodosis, 156
    - plague, 110
    - Q fever, 204–205
    - smallpox diagnosis, 226–227
    - staphylococcal enterotoxin B, 318
    - tularemia, 174–175
    - typical protocol for, 403
  - Pontiac fever
    - description, 582
  - Portal Shield Biological Warfare Agent Detection System
    - description, 445–446
  - Portugal
    - amnesic shellfish poisoning and, 371
  - Posse Comitatus Act
    - misuse of federal troops for law enforcement, 437
  - Postvaccinial encephalomyelitis
    - vaccinia complication, 230, 488–490
  - Postvaccinial encephalopathy
    - vaccinia complication, 230, 488–490
  - Powered air-purifying respirators
    - NIOSH-approved systems, 526
  - Poxviruses. *See* Buffalopox; Camelpox; Cowpox; Monkeypox; Smallpox
  - PPE. *See* Personal protective equipment
  - Prairie dogs
    - plague and, 99–100
  - Pregnant women
    - anthrax treatment, 79, 470
    - brucellosis treatment, 192
    - C jejuni* infection and, 583
    - Lassa fever and, 273
    - ribavirin and, 293, 494
    - smallpox and, 224, 229, 231, 483
    - tularemia treatment, 175
    - western equine encephalitis and, 254
  - Prince Edward Island
    - amnesic shellfish poisoning and, 371–372
  - Progressive vaccinia
    - before and after debridement (figures), 489
    - conditions at risk for developing, 230
    - description, 230
    - mortality rate, 230
    - treatment, 230, 488
  - Project BioShield
    - funding for medical countermeasures and purchase of vaccines, 574
    - purpose of, 574
    - Strategic National Stockpile and, 14
    - voluntary willingness to receive vaccines requirement, 575
  - Protective clothing. *See* Personal protective equipment
  - Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous or Other Gases and of Bacteriological Methods of Warfare, 544
  - Pseudo-nitzschia multiseriis*
    - amnesic shellfish poisoning and, 371
  - PSP. *See* Paralytic shellfish poisoning
  - Public Health Security and Bioterrorism Preparedness and Response Act
    - “fast tracking” new drugs, 573–574
    - Select Agent Program and, 535
  - Public Health Service
    - Policy on Humane Care and Use of Animals, 536
  - Public Health Service Act
    - authority for isolation and quarantine of patients, 427
    - FDA creation, 569
    - regulation of biologics, 569
  - Pujol, C.
    - intracellular replication in plague, 105
  - Pulse-field gel electrophoresis
    - glanders, 137
  - Puumala virus
    - description, 275
  - Pyridostigmine bromide
    - preexposure prophylaxis against soman intoxication, 447
  - Pyridoxine
    - amnesic shellfish poisoning treatment, 373
- ## Q
- Q fever
    - assays for the serodiagnosis of (table), 204
    - chronic form, 202–203
    - clinical manifestations, 203
    - coxiellosis in animals, 203
    - description, 202, 206, 476
    - diagnosis, 204–206
    - differential diagnosis, 200
    - disinfection procedures and products, 202
    - endocarditis and, 203, 205, 478
    - epidemiology, 202
    - former Soviet Union use of as a biological weapon, 8
    - hepatitis and, 203
    - historical background, 200
    - incidence, 202
    - incubation period, 203, 476

- infectious agent, 201–202  
infectious dose, 202  
irradiation procedure, 202  
isolation from clinical samples, 204–205  
laboratory safety issues, 200  
military relevance, 200–201  
mortality rate, 203  
occupational exposure, 202–203  
pasteurization procedures, 202  
pathogenesis, 202–203  
person-to-person transmission, 202  
pneumonia and, 203  
positive skin test (figure), 477  
potential as a biowarfare or bioterrorism agent, 476  
primary reservoirs for, 206, 476  
prophylaxis, 205–206, 478  
route of infection, 202, 476  
serologic diagnosis (table), 205  
serology, 204  
symptoms, 200, 203  
transmission, 200, 202, 206  
treatment, 205–206, 478  
vaccines, 205–206, 450, 476–478  
worldwide distribution of, 200, 202, 206
- Q-Vax  
Q fever vaccine, 206, 476–477
- Quarantine of patients  
biological agent attacks and, 416, 427  
definition, 427  
factors in compliance, 437  
severe acute respiratory syndrome and, 427  
smallpox and, 221
- Quinolones. *See also specific agents*  
brucellosis treatment, 191, 192  
melioidosis treatment and, 157  
Q fever treatment, 205  
tularemia treatment, 175
- ## R
- Rabbits  
tularemia and, 169
- Rabies  
treatment and vaccine, 519
- Rabies immune globulin  
rabies treatment, 519
- Radiography  
glanders, 137  
inhalational anthrax, 75, 78, 80  
melioidosis (figure), 154  
pneumonic plague, 107, 108  
staphylococcal enterotoxin B, 317  
tularemia, 173
- Rajneeshee cult  
*S typhimurium* contamination of food and drinking water and,  
12, 23, 46–48, 545, 584
- Rao, A.R.  
smallpox classification, 223
- “Rapid Pathogen Identification to Delivery of Cures Act”  
provisions, 575
- Rats  
*Bunyaviridae* and, 274  
plague and, 98–101
- Rauber, A.  
ricin research, 327–328
- Real-time polymerase chain reaction  
description, 404  
probe hydrolysis assays, 404  
sources for, 404
- Realtime Outbreak Detection System  
description, 60
- Recent Advances in Marine Biotechnology, Volume 7: Seafood Safety and Human Health* (Poli), 369
- Recombinant granulocyte colony-stimulation factor  
melioidosis treatment, 157
- Reed, Maj. Walter  
use of informed consent for yellow fever research subjects, 562
- Reference laboratories  
description, 522
- Relman, D.A.  
gene regulation in microassays research, 407
- Renner, S.E.  
review of potable water threats, 27
- Republic of Congo  
Ebola viruses and, 275, 276
- Republic of Georgia. *See also* Former Soviet Union  
classic symptoms of botulinum toxin in cases reported, 341
- Respirators  
facial hair and, 525–526  
fit testing, 525  
optical inserts, 526  
powered air-purifying respirators, 526  
protection factor, 525  
training in use of, 526
- Restriction fragment-length polymorphism  
smallpox diagnosis, 226, 227
- Reverse transcriptase polymerase chain reaction  
commercial assays, 404  
description, 403  
process, 403–404  
viral hemorrhagic fevers diagnosis, 288–289
- Revolutionary War  
smallpox vaccination and, 227, 544, 561
- RFLP. *See* Restriction fragment-length polymorphism
- Rhesus monkeys  
staphylococcal enterotoxin B animal model, 314–316
- Ribavirin  
adverse effects, 292–293  
contraindications, 494  
dose guidelines, 494  
mechanism of action, 493  
viral hemorrhagic fever treatment, 292–293, 492–494, 519
- Ribotyping  
glanders, 137
- Ricin. *See also* Castor beans  
agent description, 325–327  
allergic syndrome, 328  
binding, internalization, and intracellular tracking of ricin  
(figure), 326  
cancer chemotherapy and, 324–325  
case study and lessons learned, 51  
cause of death from, 330  
clinical manifestations, 327–330  
description, 51, 324, 332, 498  
diagnosis, 330–332  
differential diagnosis, 330  
extremist groups and, 325  
food supply contamination and, 332  
historical background, 324–325  
inhalation route of administration, 326, 328–332, 498  
injection route of administration, 326, 328, 331  
lethal dose, 326  
leukocyte counts and, 327  
lung from a monkey exposed to (figure), 329  
lung from a rat exposed to (figure), 329

- mailings of packages contaminated with, 14, 51
  - median lethal doses for aerosolized ricin in various animal species (table), 326
  - Minnesota Patriots Council production and planned use of, 12
  - mortality rates, 327–328
  - oral route of administration, 326–328, 331, 498
  - pathogenesis, 326–327
  - postexposure prophylaxis, 498
  - potential biowarfare and bioterrorism threat, 324–325, 332
  - side effects, 324
  - supportive therapy, 331
  - symptoms of exposure, 327, 332
  - toxicity, 325–326
  - treatment, 328
  - vaccines for, 331–332, 498
  - vascular leak syndrome and, 324–325, 498
  - Ricinus communis*. *See* Castor beans; Ricin
  - Rifampin
    - brucellosis treatment, 191–192, 476
    - glanders treatment, 475
  - Rift Valley fever virus
    - aerosol transmission, 274
    - clinical manifestations, 279
    - description, 274
    - disseminated intravascular coagulation and, 286
    - epizootics, 274
    - ribavirin treatment, 293
    - risk factors for human infection, 274
    - transmission electron micrograph (figure), 277
    - vaccine for, 290, 492
    - weaponization of, 276
  - Riluzole
    - clostridial toxin treatment, 376
  - Risk groups
    - assigning of, 517–518
    - exposure risks in laboratories, 620
    - placement of agents in, 518–520
    - relationship of risk groups, biosafety levels, practices, and equipment (table), 518
  - RiVax
    - ricin vaccine, 331, 498
  - Robert T. Stafford Disaster Relief and Emergency Assistance Act provisions, 416
  - Robins, G.D.
    - glanders research, 126, 128, 134
  - Rocky Mountain Regional Care Model for Bioterrorist Events
    - lists of equipment and consumables, 432
  - RODS. *See* Realtime Outbreak Detection System
  - Roosevelt, Pres. Franklin D.
    - biological warfare research, 5
  - Roseola vaccinatium
    - figure, 487
  - Ross River virus. *See* *Alphavirus* encephalitis
  - Rotz, L.D.
    - tularemia research, 169
  - RT-PCR. *See* Reverse transcriptase polymerase chain reaction
  - RTA 1-33/44-198
    - ricin vaccine, 331, 498
  - Ruf, W.
    - tissue factor in viral hemorrhagic fevers, 286
  - Rush, Benjamin
    - dengue fever research, 276
  - Russia. *See also* Former Soviet Union
    - agreement with the United States and Great Britain promising to end its biological weapons program, 10
    - botulinum toxin development for use as a biological weapon, 339
    - weaponization of viral hemorrhagic fevers, 276
  - RVF. *See* Rift Valley fever virus
- ## S
- S aureus*
    - antibiotic resistance, 587
    - description of the agent, 312–314
    - molecular model of receptor binding (figure), 313
    - virulence factors, 312
  - S dysenteriae*
    - case study and lessons learned from the Dallas, TX, outbreak, 49–50
    - complications from, 24
  - S marcescens*
    - aerosol vulnerability tests conducted in San Francisco, 6
  - S pyogenes*
    - description of the agent, 312–314
    - molecular model of receptor binding (figure), 313
    - virulence factors, 312
  - S typhi*
    - Suzuki's contamination of food items with, 15
    - typhoid fever cause, 23, 584
  - S typhimurium*
    - antibiotic resistance, 23
    - Japan's poisoning of wells with during World War II, 23
    - outbreak case study and lessons learned, 46–48
    - Rajneeshee cult contamination of food and drinking water with, 12, 23, 46–48, 545, 584
    - symptoms of infection, 47
  - Sabia virus
    - description, 274
    - ribavirin treatment, 293
  - Saddam Hussein
    - Iraq's biological weapons program and, 11
  - Saiki, R.K.
    - polymerase chain reaction research, 403
  - Sakurai, J.
    - clostridial toxin research, 376
  - Salk Institute
    - eastern equine encephalitis vaccine manufacture, 481
  - Salmonella*. *See also* Salmonellosis
    - antibiotic resistance, 29, 587
    - vehicles for infection, 23
  - Salmonellosis
    - case study and lessons learned, 46–48
    - clinical manifestations, 584
    - milk-borne salmonellosis, 23
    - mortality rate, 584
    - outbreak in The Dalles, OR, 23, 46–48, 584
    - principal route of disease, 46, 584
    - underreporting of cases, 46
  - Sampath, R.
    - TIGER research, 405
  - San Francisco, CA
    - open-air tests of pathogens, 6
    - plague epidemic, 102
  - Sarin
    - Aum Shinrikyo cult's sarin attack in the Tokyo subway, 12, 339, 427, 545
  - SARS. *See* Severe acute respiratory syndrome
  - Saudi Arabia
    - Alkhurma virus and, 276
  - Saxitoxin. *See* Paralytic shellfish poisoning
  - Schwartz, Dr. Martin
    - Colorado potato beetle research, 27
  - Scotland
    - amnesic shellfish poisoning and, 371

- Scrofula  
 plague differential diagnosis, 109
- Scrub typhus  
 plague differential diagnosis, 109
- Seafood. *See* Marine algal toxins
- SEB. *See* Staphylococcal enterotoxin B
- Select Agent Program  
 laboratory registration, 535  
 legislation for, 535
- Sentinel laboratories  
 Basic Protocols for Level A (Sentinel) Laboratories, 395  
 description, 522
- Seoul virus  
 description, 275  
 geographic distribution, 275
- Septicemic plague  
 acral cyanosis and necrosis (figures), 107  
 causes, 92  
 clinical manifestations, 105  
 cutaneous manifestations, 108  
 diagnosis, 107  
 differential diagnosis, 210  
 mortality rate, 105, 107  
 transmission route, 105
- SERPACWA skin exposure reduction paste  
 trichothecene mycotoxins and, 364
- Severe acute respiratory syndrome  
 causative agent, 590  
 description, 590  
 exotic animals used for food and, 580  
 global outbreak, 590  
 live animal markets and, 590–591  
 masked palm civet implication as the possible source for the SARS coronavirus (figure), 591  
 quarantine of patients, 427
- Sheep  
 brucellosis and, 186  
 Q fever and, 201, 203, 206
- Shellfish. *See* Marine algal toxins
- Shigella*. *See also* Shigellosis  
 incubation period, 24  
 infectious dose, 24  
 Japan's attacks against Chinese nationals with, 4  
 transmission, 24
- Shigellosis  
 case study and lessons learned from the Dallas, TX, outbreak, 49–50
- Siberia  
 tularemia and, 170
- Simonson, Stewart  
 botulinum toxin research publication and, 339
- Sin Nombre virus  
 description, 275  
 epidemic of, 42
- Sindbis virus. *See* *Alphavirus* encephalitis
- Singapore  
 quarantine of patients with SARS, 427  
 severe acute respiratory syndrome and, 590
- Slovetsky Island  
 typhus experimentation by the former Soviet Union on political prisoners, 8
- Smallpox  
 adverse events after smallpox vaccination (table), 485  
 allergic response to vaccination, 229, 230  
 antiviral drug treatment, 216, 231–233  
 biosafety risk group assignment, 518  
 case study and lessons learned, 51–52  
 CDC free planning software for large-scale smallpox prophylaxis clinics, 434, 436  
 CDC's vaccination strategy, 14  
 clinical aspects of infections, 221–224, 445  
 clinical diagnosis, 225  
 complications from, 224  
 contraindications to smallpox vaccination (pre-event vaccination program) (table), 484  
 contraindications to vaccination, 229–230, 483–490  
 description, 216, 481  
 DNA sequencing, 226–227  
 early experiments with variolation, 227, 544  
 eczema vaccinatum, 485, 487  
 flat type, 223–224  
 flow diagram for a campaign responding to smallpox or other communicable agent (figure), 435  
 former Soviet Union's accidental release of smallpox in Aralsk, 51–52  
 handling corpses infected with, 436  
 hemorrhagic type, 223–224  
 history of smallpox vaccination, 481–482  
 hospital infection control precautions, 429  
 immunodiagnosis, 226  
 impact of a virus attack in the human population, 216  
 inadvertent transmission after vaccination, 230, 483, 486  
 incubation period, 216, 221  
 infection of Native Americans with, 2–3, 220  
 introduction of disease to the Aztec empire, 2  
 Jennerian response to vaccination, 229  
 laboratory diagnosis, 225–226  
 Modified Vaccinia Ankara vaccine, 229, 449  
 mortality rates, 216, 223  
 multifaceted response to, 449  
 new vaccine research, 490–491  
 nucleic acid diagnosis, 226–227  
 open-air testing by the former Soviet Union, 216, 220  
 passive immunization, 231  
 phenotype diagnosis, 226  
 potential biowarfare threat from, 216, 228, 231, 233, 490  
 precautions for smallpox vaccination (pre-event vaccination program) (table), 485  
 primary reaction to smallpox vaccination (figure), 482  
 production and storage of by the Soviet Union as a strategic weapon, 216  
 prophylaxis, 227–231, 490–492  
 protective clothing and, 447  
 quarantine for cases, 221  
 replication, 221  
 risk-benefit analysis of widespread civilian vaccination for, 448–449  
 routine vaccination of U.S. children, 482  
 secondary attack rates from smallpox in unvaccinated persons, 482–483  
 skin lesion evolution (figures), 222  
 skin lesions, 221–223  
 thin section of virus (figure), 217  
 transmission, 216, 221  
 transmission-based precautions, 456  
 treatment, 231–233, 491–492  
 undeclared repositories, 220  
 vaccination complications, 228, 230–231, 448–449, 483–490  
 vaccination outcome, 229  
 vaccines for, 216, 224, 227–231, 233, 448–449, 467, 481–491  
 variola major form, 223  
 variola minor form, 223  
*variola sine eruptione*, 224  
 WHO eradication program, 9, 216

- Smallshaw, J.E.  
ricin research, 324–325
- Smirnov, Col. Gen. Yefim  
former Soviet Union biological warfare program and, 8
- SNS. *See* Strategic National Stockpile
- Sodium valproate  
amnesic shellfish poisoning treatment, 373
- Soman intoxication  
pyridostigmine bromide prophylaxis, 447
- South Africa  
biological weapons program, 10  
Crimean-Congo hemorrhagic fever and, 274
- South America. *See also specific countries*  
*Alphavirus* encephalitis and, 242, 244  
cholera outbreaks, 581  
dengue fever and, 276, 593  
glanders and, 122, 125  
paralytic shellfish poisoning and, 367  
plague incidence, 101  
smallpox and, 223  
yellow fever and, 276
- South Dakota  
tularemia outbreaks, 169
- Southern tick-associated rash illness  
causative agent, 586  
description, 586
- Spain  
amnesic shellfish poisoning and, 371  
tularemia and, 169, 175
- Specimen collection and processing  
biosafety precautions, 397  
most common specimens collected, 397
- Squirrels  
plague and, 100–101
- ST-246  
smallpox treatment, 492
- Stachybotryotoxicosis  
description, 357
- Stafford Act. *See* Robert T. Stafford Disaster Relief and Emergency Assistance Act
- Stalin  
biological warfare program, 8
- Stanton, A.T.  
melioidosis research, 148
- Staphylococcal enterotoxin B  
antibody-based therapy, 314  
ban on offensive toxin weapons and, 312  
cardiovascular symptoms, 317  
clinical manifestations, 315–318, 497  
diagnosis, 312, 318–319  
fever and, 317  
food poisoning and, 312, 497  
headache and, 317  
hematology, 317  
immunotherapy, 318  
laboratory-acquired infection with, 317–318  
lethal dose, 312  
lung of a rhesus monkey infected with (figure), 315  
mediastinal lymph nodes of a rhesus monkey infected with (figure), 316  
medical management, 318–319  
nausea and vomiting and, 317  
ocular effects, 318  
pathogenesis, 314–316  
postexposure prophylaxis, 498  
respiratory symptoms, 317  
ricin and, 324  
ricin differential diagnosis, 330  
small intestine of a rhesus monkey infected with (figure), 316  
supportive therapy, 318–319  
toxic shock and, 314  
vaccines, 314, 319, 497–498  
vascular changes and, 316
- STARI. *See* Southern tick-associated rash illness
- Sterilizers  
laboratory use, 529  
types of, 529
- Sternberg, Surgeon General George  
appointment of Maj. Walter Reed to the Yellow Fever Commission, 562
- Stillmark, Hermann  
ricin research, 324
- Stimson, Secretary of War Henry L.  
Japan's attempt to obtain yellow fever virus strains from Rockefeller University and, 562
- Strategic National Stockpile  
coordinated plan for logistics and, 433  
description, 13  
items included, 432  
local response to a biological attack and, 432–433  
National Response Plan and, 421  
Project Bioshield and, 14  
technical advisory response unit, 432–433
- Streptococcal adenitis  
plague differential diagnosis, 109–110
- Streptococcus pyogenes*  
antibiotic resistance, 587
- Streptomycin  
brucellosis treatment, 191–192  
glanders treatment, 140  
plague treatment, 111  
tularemia treatment, 175, 473
- Sulfadiazine  
glanders treatment, 135, 139, 140
- Sulkin, S.E.  
laboratory-acquired infection research, 551
- Superantigens. *See* *S aureus*; *S pyogenes*
- Suzuki, Dr. Mitsuru  
contamination of food items with *Salmonella typhi* and agents of dysentery, 15
- Sweden  
tularemia outbreaks, 170
- Swimming pools  
*E coli* 0157:H7 and, 24, 580  
*Giardia lamblia* and, 27  
*Shigella* infection and, 24, 580
- Syndromic surveillance  
data collection, 59  
description, 59  
Electronic Surveillance System for the Early Notification of Community-based Epidemics, 59  
future uses, 60  
limitations of programs, 60

## T

- T-2 toxin. *See* Trichothecene mycotoxins
- Taiwan  
quarantine of patients with SARS, 427
- Tapeworms  
bioterrorism potential, 25
- Tatlock, Hugh  
*Legionella pneumophila* isolation, 582
- TC-83 vaccine  
adverse events, 479

- components, 479
- description, 478–479
- lot release testing, 479
- Venezuelan equine encephalitis, 248, 256–258, 478–479
- Tetracycline
  - anthrax treatment, 79
  - brucellosis treatment, 191
  - glanders treatment, 140
  - melioidosis treatment, 475
  - plague treatment, 474
  - Q fever treatment, 205, 478
  - tularemia prophylaxis, 176, 473
  - tularemia treatment, 175
- Tetravalent vaccine
  - botulinum toxin treatment candidate, 346
- Texas
  - Dallas outbreak of *S dysenteriae*, 49–50
  - Venezuelan equine encephalitis outbreaks, 243
- Thailand
  - castor bean cultivation, 324
  - melioidosis and, 153–154, 156–157, 475
- Thin-layer chromatography
  - amnesic shellfish poisoning diagnosis, 372
  - trichothecene mycotoxins, 363
- Thompson, Diane
  - infection of coworkers with *Shigella dysenteriae*, 15
- Thompson, Tommy
  - warning of possible attack on the nation's food supply, 29
- Ticks
  - Bunyaviridae* and, 274, 287
  - ehrlichiosis and, 586–587
  - Flaviviridae* and, 276
  - Lyme disease and, 585–586
  - Q fever and, 200
  - southern tick-associated rash illness and, 586
  - tularemia and, 169–170, 172
  - viral hemorrhagic fevers and, 287
- TIGER. *See* Triangulation identification for genetic evaluation of risks
- Tigertt, Col. William
  - U.S. Army Medical Unit under (figure), 567
- Time-resolved fluorescence
  - description, 401
  - dissociation-enhanced lanthanide fluorescence immunoassay, 401
- Tioman virus
  - description, 592
- TLC. *See* Thin-layer chromatography
- TMP-SMX. *See* Trimethoprim/sulfamethoxazole
- Toxic shock syndrome
  - causative organisms, 313
  - clinical manifestations, 316–318
  - immune globulin therapy, 314
  - toxin description, 312–313
- TRF. *See* Time-resolved fluorescence
- Triangulation identification for genetic evaluation of risks
  - description, 404–405
- Trichothecene mycotoxins
  - aerosol exposure, 356–357, 361, 364
  - agricultural workers exposed to hay or hay dust and, 361
  - autoclaving and elimination of, 358
  - cell membrane interactions, 359
  - chemical and physical properties, 358
  - clinical manifestations, 359–362
  - confirmatory diagnosis procedures, 363–364
  - cytotoxicity, 358
  - dermal exposure, 359–360
  - description, 356
  - diagnosis, 362–364
  - domestic farm animals and, 357
  - DS-2 decontaminating agent, 358
  - early signs and symptoms, 362
  - environmental assays, 363
  - former Soviet Union's deployment of as “yellow rain” in Laos, Cambodia, and Afghanistan, 7, 25, 356, 545
  - historical background, 356–357
  - immunoassay kits for detecting, 363
  - ingestion of foods contaminated with, 361, 364
  - later signs and symptoms, 362
  - lethal dose, 356
  - mechanism of action, 358–359, 377
  - medical management, 364–365
  - moldy grains, cereals, and agricultural products and, 357
  - monoclonal antibodies and, 365
  - mortality rate, 360–361
  - natural occurrence, 357
  - ocular exposure, 360–361, 364
  - parenteral exposure, 361–362, 364
  - percutaneous exposure, 356–357, 359–360
  - potential for use as biowarfare or bioterrorism agents, 356, 363
  - preexposure treatment and decontamination, 364
  - presumptive diagnosis, 362–363
  - prophylaxis, 365
  - protective clothing and, 364
  - respiratory exposure, 361–362, 365
  - RNA synthesis inhibition, 358–359
  - scheduled DNA synthesis, 359
  - screening tests, 363
  - SERPACWA skin exposure reduction paste, 364
  - skin lesions (figure), 360
  - stachybotryotoxicosis, 357
  - symptoms of infection, 357
  - toxin description, 357–358, 377
  - treatment, 364–365, 377
  - use in cancer therapy, 357
  - water-damaged buildings and, 361, 363
  - weaponization, 356–357
- Trifluridine
  - vaccinia treatment, 230, 483
- Trimethoprim/sulfamethoxazole
  - brucellosis treatment, 191, 476
  - glanders treatment, 140
  - melioidosis treatment, 156–157, 475
  - plague treatment, 474
- TSS. *See* Toxic shock syndrome
- Tuberculosis
  - antibiotic resistance, 587
  - handling corpses infected with, 436
  - plague differential diagnosis, 109
- Tucker, J.B.
  - biocrimes analysis, 15
- Tularemia. *See also F tularensis*
  - aerosol transmission, 170
  - antibiotics for postexposure prophylaxis (table), 176
  - antibiotics for the treatment of tularemia (table), 175
  - arthropod vectors, 169–171
  - bacterial culture techniques, 174
  - cause, 55
  - cell-mediated immunity, 472–473
  - clinical manifestations, 169, 172–173, 177
  - description, 55, 168–169, 471
  - diagnosis, 173–175, 177
  - differential diagnosis, 77, 177
  - direct contact transmission, 169

- disease progression, 55
- epidemiology, 169, 177
- food and water ingestion, 169
- former Soviet Union use of as a biological weapon, 8, 168
- glandular type, 172
- hospital infection control precautions and, 429
- immune system response, 171–172
- infectious agent, 168, 471
- Kosovo outbreak, 55–56, 168, 170
- laboratory-acquired infection, 170
- laboratory findings, 173
- laboratory safety issues, 173, 177
- link with grass cutting, 170
- low infectious dose, 171
- mammalian bites, 169–170
- Martha's Vineyard, MA, outbreak, 54–55, 170, 173
- mortality rates, 173, 175
- oculoglandular type, 172
- oropharyngeal type, 169, 172–173
- pathogenesis, 170–172
- plague differential diagnosis, 109
- pneumonic type, 169, 173, 177
- potential bioterrorism threat of, 168, 173–174, 177, 471
- prophylaxis, 176–177, 473
- rapid diagnostic methods, 174–175
- septic type, 173
- serology, 174
- subspecies, 168, 169
- transmission, 56, 169–170, 471
- treatment, 174–175, 177, 473
- typhoidal type, 169, 172–173, 177, 471
- ulceroglandular type, 169, 172–173, 177, 471
- unusual settings, 170
- vaccines, 171–172, 176–177, 450, 471–473
- virulence factors, 172
- Turkey
  - tularemia and, 169, 173
- Turner, Rep. Jim
  - "Rapid Pathogen Identification to Delivery of Cures Act" and, 575
- Turner Bill. *See* "Rapid Pathogen Identification to Delivery of Cures Act"
- 20th Support Command
  - support capabilities, 422
- Type III secretion system
  - plague and, 103
- Type IV secretion system
  - brucellosis and, 188
- Typhoid fever
  - S typhi* and, 23
  - symptoms, 23
- Typhus
  - experimentation by the former Soviet Union on political prisoners, 8
  - Poland's pseudoepidemics of during World War II, 4

## U

- Uganda
  - Ebola viruses and, 275
  - gastrointestinal anthrax outbreak, 583
  - West Nile virus and, 594
- Ulrich, R.G.
  - clostridial toxin research, 376
- UN Special Commission on Iraq
  - Iraq's biological weapons program and, 11, 15
- Uneo, Y.
  - trichothecene mycotoxins research, 358
- United Kingdom
  - agricultural and food losses from outbreaks of foot and mouth disease, 28
  - Colorado potato beetle outbreaks during World War II, 27
  - containment care, 423
  - equine glanders (and farcy) in Great Britain: 1877–1928 (figure), 124
  - glanders eradication, 123–124
  - Lassa fever and, 273
  - ricin research, 325
  - use of secret open-air tests of pathogens after World War II, 4–5
  - World War II biological warfare program, 4–5
- United Nations
  - Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction, 7–8, 15, 122–123, 325, 338, 545
- United States. *See also specific states, cities, and federal government departments and agencies*
  - agreement with the former Soviet Union promising to end its biological weapons program, 10
  - amnesic shellfish poisoning and, 371
  - anthrax vaccination, 79–80
  - biological agents produced by the U.S. military (destroyed 1971–1973) (table), 5
  - biological preparedness program, 12–14
  - botulinum toxin development for use as a biological weapon, 339
  - botulism outbreaks, 584
  - brucellosis and, 186, 187
  - cholera cases, 581
  - Colorado potato beetle outbreaks during World War II, 27
  - contaminated drinking water disease outbreaks, 580
  - Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological and Toxin Weapons and on their Destruction and, 15, 122–123, 545
  - eastern equine encephalitis and, 243, 244
  - foodborne illness burden, 582
  - funding for anthrax studies, 71
  - glanders and, 122–125, 138
  - historical background of biological warfare program, 5–6, 544–545
  - Lassa fever and, 273
  - Lyme disease and, 585–586
  - marine algal toxins monitoring programs, 366
  - melioidosis and, 149–151
  - Minnesota Patriots Council production and planned use of ricin, 12
  - monkeypox and, 225–227
  - paralytic shellfish poisoning and, 369
  - plague and, 93–95, 99–102, 105
  - plague cycles in the United States (figure), 100
  - plague risks at U.S. military installations (table), 95
  - Q fever and, 200
  - ricin and, 327
  - ricin research, 325
  - Sin Nombre virus, 42, 275
  - smallpox vaccination program, 227–228
  - spread of West Nile virus across the United States 1999–2004 (figure), 595
  - stachybotryotoxicosis and, 357
  - tularemia and, 169
  - use of secret open-air tests of pathogens after World War II, 4–6
  - Venezuelan equine encephalitis and, 248
  - weaponization of viral hemorrhagic fevers, 276

- West Nile virus outbreaks, 41–42, 53–54, 594–595, 597
- western equine encephalitis and, 244
- University of Pittsburgh
  - Realtime Outbreak Detection System, 60
- UNSCOM. *See* UN Special Commission on Iraq
- U.S. Air Force. *See also* U.S. Air Force Institute for Operational Health
  - biological augmentation teams, 394
- U.S. Air Force Institute for Operational Health
  - identifying and confirming the presence of biological threats, 392
  - Laboratory Response Network responsibilities, 394
- U.S. Army
  - controls for access to biological select agents and toxins, 395
  - personnel reliability program, 397, 551–555
- U.S. Army Biosurety Program
  - agent accountability, 555–556
  - basic concepts, 550–555
  - biological personnel reliability program, 551–555
  - biosafety component, 550–551
  - corporate approach for the safe, secure and authorized use of biological select agents and toxins, 549–550
  - focus of, 549
  - physical security component, 550–551
  - pillars of biosurety and pillar components (table), 550
- U.S. Army Chemical Warfare Service Laboratories
  - air filtration technology, 517
- U.S. Army Medical Research and Materiel Command
  - laboratory safety audits, 534
- U.S. Army Medical Research Institute of Infectious Diseases
  - anthrax assays, 421
  - anthrax vaccine study, 469
  - bivalent recombinant botulinum vaccine development, 346
  - botulism antitoxins, 343–344
  - CM4884 vaccine and, 480–481
  - creation and mission of, 8
  - enzyme-linked immunosorbent assay for glanders, 137
  - HEPA-filtered animal transport carts, 525
  - identifying and confirming the presence of biological threats, 392
  - Junin vaccine, 290
  - Laboratory Response Network responsibilities, 394
  - laboratory safety audits, 534–535
  - Medical Management of Biological Casualties Handbook*, 445–460
  - military biosecurity program framework, 395
  - patient-containment care suite, 423–424
  - pentavalent botulinum toxoid potency testing, 345
  - research effort focus, 522
  - review of occupational exposure to tularemia, 177
  - ricin detection and, 331
  - stepwise approach to casualty management that might result from biological warfare or bioterrorism, 444–460
  - tularemia vaccine administration, 176–177, 471
  - viral hemorrhagic fever biosafety issues, 288
- U.S. Chemical Warfare Service
  - ricin as a biowarfare agent, 325
- U.S. Coast Guard
  - emergency support functions, 418
- U.S. Congress. *See specific legislation*
- U.S. Department of Agriculture
  - Animal and Plant Health Inspection Service Select Agent Program Laboratory Inspection Program, 534
  - Animal and Plant Health Inspection Service's select agent and toxin list of pathogens and toxins, 28
  - clostridial toxins threat, 374
  - controls for access to biological select agents and toxins, 395
  - estimate of medical costs and productivity losses for diseases caused by leading foodborne pathogens, 22
  - foot and mouth disease protective measures, 28
  - foreign animal disease outbreaks and, 138
  - glanders and, 138, 141
  - laboratory safety audits, 534
  - National Veterinary Services Laboratory investigation of the West Nile virus outbreak in New York City, 53
  - open-air tests of anticrop agents, 6
  - regulated biological select agents and toxins (exhibit), 393
  - responsibility for developing regulations to control access to and possession of biowarfare threat agents, 546
  - responsibility for food safety, 29
  - S typhimurium* outbreak in The Dalles, OR, 47
  - trichothecene mycotoxin detection kits, 363
- U.S. Department of Defense
  - Biological Surety Program, 395, 536, 549–556
  - bioterrorism response assets, 421–424
  - BSL-4 facility certification, 524
  - cidofovir treatment for smallpox and monkeypox, 231
  - controls for access to biological select agents and toxins, 395
  - coordination of civilian medical countermeasure development, 14
  - defense coordinating officer, 419–420
  - Defense Safety Program, 396
  - Electronic Surveillance System for the Early Notification of Community-based Epidemics, 59
  - enzyme-linked immunosorbent assay development, 400
  - Homeland Defense Coordination Office, 420
  - Joint Biological Agent Identification and Diagnostic System and, 407–408
  - lateral flow assays and, 402
  - memoranda of understanding with the FDA on Investigational New Drugs, 569, 570
  - military involvement in law enforcement under certain conditions, 437
  - National Response Plan and, 13
  - Nuremberg Code and, 565–566
  - pentavalent botulinum toxoid availability, 495
  - pentavalent botulinum toxoid development, 345
  - personnel reliability program, 397, 551–555
  - Portal Shield Biological Warfare Agent Detection System, 445–446
  - real-time polymerase chain reaction assay development, 404
  - research, development, test, and evaluation (RDTE) laboratories, 534–536
  - Smallpox Response Plan, 225
  - support to civilian authorities, 420
  - Use of Volunteers as Subjects of Research*, 565
- U.S. Department of Energy
  - real-time polymerase chain reaction assay development, 404
- U.S. Department of Health and Human Services
  - anthrax vaccine stockpile, 14
  - assistance from the U.S. Department of Defense, 420
  - authority for isolation and quarantine of patients, 427
  - “Biosafety in Microbiological and Biomedical Laboratories,” 394–395
  - Bioterrorism and Epidemic Response Model, 433–434
  - bioterrorism response, 13
  - cidofovir treatment for smallpox and monkeypox, 231
  - controls over access to biological select agents and toxins, 395
  - emergency support functions, 418, 420–421
  - Health Resources and Services Administration benchmarks for hospitals in the National Bioterrorism Hospital Preparedness Program, 429
  - Modified Vaccine Ankara smallpox vaccine trials, 449
  - Office of Public Health Emergency Preparedness, 14
  - regulated biological select agents and toxins (exhibit), 393

- report on *C botulinum* contamination potential and, 23
  - responsibility for developing regulations to control access to and possession of biowarfare threat agents, 546
  - responsibility for food safety, 29
  - stockpiling of smallpox vaccine doses, 449
  - U.S. Department of Homeland Security
    - BioWatch program, 59
    - establishment of, 13–14, 417
    - foreign animal disease outbreaks and, 138
    - glanders and, 142
    - National Bioforensic Analysis Center, 406
    - National Disaster Medical System, 458
    - Office of Emergency Response, 458
    - responsibilities, 417
    - secretary's coordination of federal incident management activities, 417–419
    - Weapons of Mass Destruction Medical Countermeasures Subcommittee, 14
  - U.S. Department of State
    - report on biological warfare programs in violation of the BWC, 15
  - U.S. Department of the Army
    - Biological Defense Safety Program, 536
  - U.S. Department of Veterans Affairs
    - excess hospital bed capacity, 458
  - U.S. Environmental Protection Agency
    - disinfectant products, 529
  - U.S. Food and Drug Administration
    - Alphavirus* encephalitis vaccines, 259
    - animal rule for vaccines, 467
    - anthrax vaccine, 10–11, 448
    - botulinum toxin use for cosmetic purposes, 344
    - botulism preparations for cosmetic use, 342
    - botulism treatment, 343
    - creation of, 569
    - DoD deployments and, 571–572
    - Emergency Use Authorization for Promising Medical Countermeasures, 574–575
    - FDA Kefauver-Harris Drug Amendments and, 569
    - Investigational New Drugs, 570–574
    - memoranda of understanding with DoD on Investigational New Drugs, 569–570
    - new cell-culture derived vaccinia licensing, 449
    - over-the-counter lateral flow assays, 402
    - relationship with the military, 560
    - responsibility for food safety, 29
    - ribavirin and, 292–293
    - tularemia vaccine, 176
  - U.S. Government Interagency Domestic Terrorism Concept of Operations Plan
    - National Response Plan integration of, 417
  - U.S. Naval Research Laboratory
    - glass-filter paper development, 517
  - U.S. Navy
    - forward deployable preventive medicine units, 394
  - U.S. Northern Command
    - civil support capabilities, 422
    - Joint Task Force Civil Support, 422
  - U.S. Postal Service
    - anthrax mailings and, 13, 50–51, 71, 545–546
  - U.S. Public Health Service
    - anthrax mailing investigation, 433
    - postexposure prophylaxis for postal workers possibly exposed to anthrax, 433
    - responsibility for food safety, 29
  - USAMRIID. *See* U.S. Army Medical Research Institute of Infectious Diseases
  - USDA. *See* U.S. Department of Agriculture
  - Use of Volunteers as Subjects of Research*, 565
- ## V
- V parahaemolyticus*
    - clinical manifestations, 581
    - seafood consumption and, 581
  - V3526 vaccine
    - Venezuelan equine encephalitis and, 481
  - V vulnificus*
    - clinical manifestations, 581
    - shellfish consumption and, 581
  - Vaccine Adverse Event Reporting System
    - anthrax vaccine data, 469
  - Vaccines
    - anthrax, 79–80, 448, 467–471
    - Argentine hemorrhagic fever, 290, 492
    - at-risk personnel and, 527–528
    - Biologics Control Act and, 569
    - biosafety risk groups and, 519
    - botulinum toxin, 345–346, 450, 571
    - cholera, 581
    - clostridial toxins, 375–377
    - contraindications for subject participation in vaccination programs, 528
    - eastern equine encephalitis, 256, 258–259, 481
    - Ebola viruses, 292, 492
    - factors in a decision to use, 448
    - FDA animal rule, 467
    - Investigational New Drug examples, 528
    - licensed vaccine examples, 527–528
    - medical management of potential biological casualties and, 447–450
    - plague, 92, 94, 112–113, 450, 473–474
    - Project BioShield and, 574
    - Q fever, 205–206, 450
    - rabies, 519
    - Rift Valley fever virus, 492
    - smallpox, 216, 224, 227–231, 481–491
    - staphylococcal enterotoxin B, 314, 319, 497–498
    - tularemia, 171–172, 176–177, 450, 471–473
    - vaccines, vaccine dosage schedules, and postvaccination protection (table), 466
    - Venezuelan equine encephalitis, 244, 256, 258–259, 450, 478–481
    - western equine encephalitis, 244, 256, 258–259, 480–481
    - yellow fever, 290, 450, 492
  - Vaccinia
    - clinical manifestations, 483–484
    - description (figure), 487
    - fetal (figure), 489
    - ocular type (figure), 486
    - progressive type, 230, 487–488
    - treatment, 230, 231
  - Vaccinia immune globulin
    - administration for complications of smallpox (vaccinia) vaccination (table), 486
    - effectiveness of, 491
    - limited supplies of, 491
    - progressive vaccinia treatment, 488
    - vaccinia treatment, 230–231, 448, 483
  - Valacyclovirhydrochloride
    - herpes B virus treatment, 519
  - VALTRESX
    - herpes B virus treatment, 519
  - Vancomycin
    - anthrax treatment, 79

- resistance to, 587
- Variola virus. *See* Smallpox
- Variolation  
early experiments with, 227, 544, 561
- Vascular leak syndrome  
ricin and, 324–325, 498
- VEE. *See* Venezuelan equine encephalitis
- Venezuela  
Guanarito virus, 274  
Venezuelan equine encephalitis and, 242–243, 247, 250
- Venezuelan equine encephalitis  
clinical manifestations, 242, 252–253  
components of the virus complex, 244  
description, 242  
diagnosis, 253  
enzootic strains, 244, 246–247  
epizootic strains, 244, 246–248, 252, 256  
incubation period, 252  
isolation of, 242–243  
laboratory-acquired infection, 242  
live vaccines, 257–258  
morbidity rate, 246  
mortality rate, 243  
nasal tissue after exposure (figure), 251  
neuroinvasion mechanism, 251–252  
olfactory bulb after exposure (figure), 251  
passive immunization, 256–257  
pathogenesis, 250–252  
Trinidad donkey strain, 251  
vaccines, 244, 256, 258–259, 450, 478–481  
vaccines available for VEE, EEE, and WEE viruses (table), 257  
Venezuelan equine encephalomyelitis complex (table), 247
- VHFs. *See* Viral hemorrhagic fevers
- Vibrio cholerae*  
Japan's attacks against Chinese nationals with, 4  
water supply issues, 27
- Vidarabine  
vaccinia treatment, 230, 483
- Vietnam  
endemic plague, 94  
severe acute respiratory syndrome and, 590
- Vietnam War  
endemic plague and, 94  
melioidosis and, 150, 156
- VIG. *See* Vaccinia immune globulin
- Viral hemorrhagic fevers. *See also specific diseases, i.e., Ebola virus*  
active vaccination, 290–292  
aerosol transmission, 272  
agent characteristics, 277–278  
antiviral therapy, 292–293, 492–494  
*Arenaviridae*, 272–274, 277, 293  
*Bunyaviridae*, 274–275, 277–278, 293  
causative viral agents, 272  
cDNA microarrays and, 287  
clinical manifestations, 272, 278–280, 287  
coagulation abnormalities, 272, 285–286  
description, 272  
diagnosis, 287–289  
differential diagnosis, 287–288  
disseminated intravascular coagulation and, 285–286  
epidemiology, 272–277  
*Filoviridae*, 275–276, 278–280, 293  
*Flaviviridae*, 276, 278, 280, 293  
future directions in pathogenesis, 287  
geographic ranges, 272  
handling corpses infected with, 436  
historical background, 272–277  
hospital infection control precautions, 429  
hospital spread, 272  
host immune response, 272, 293–294  
immunohistochemical staining (figure), 288  
immunoprophylaxis, 293  
immunosuppression mechanism, 283–284  
incubation period, 279  
infection control and, 495  
inflammatory response, 284–285  
isolation and containment issues, 290  
laboratory findings, 280, 287  
laboratory safety issues, 277  
lesions, 280  
lethal doses, 272  
liver pathology (figure), 279  
lymphoid depletion (figure), 283  
medical countermeasures for (table), 493  
medical management, 289–290  
model of viral hemorrhagic fever pathogenesis (figure), 281  
modulation of the host immune response, 293–294  
mortality rates, 272, 276, 279  
ocular manifestations (figure), 279  
passive immunotherapy, 494–495  
pathogenesis, 280–287  
postexposure vaccination, 292  
potential role in biowarfare or bioterrorism, 272, 276–277, 294, 494  
prevention and control, 290–294  
prevention and control of viral hemorrhagic fevers in humans (table), 291  
replication of viruses, 272  
reverse genetics systems and, 287  
ribavirin treatment, 292–293, 492–494, 519  
secondary infections and, 289–290  
shock-like syndrome, 280  
specific diagnosis, 288–289  
supportive treatment, 289, 292, 494  
target cells and tissues, 282–283  
thrombocytopenia and, 285–286, 287  
transmission-based precautions, 456  
transmission electron micrographs (figure), 277  
treatment of bleeding, 289  
treatment of hypotension and shock, 289–290  
vectors, 272
- Virginia  
anthrax and glanders events of 1915–1916 case study, 45–46  
eastern equine encephalitis and, 242–243  
Ebola virus strain, 275
- Vistide  
cytomegalovirus treatment, 231–232
- Vitek 1 and 2  
melioidosis identification kits, 156
- VSL. *See* Vascular leak syndrome

## W

- Waag, D.M.  
tularemia vaccine research, 172
- Washington  
amnesic shellfish poisoning and, 371
- Washington, Pres. George  
smallpox vaccination and, 227, 544, 561
- Washington University  
academic biosafety fellowship program, 537
- Water supply issues. *See also* Food and water security; Swimming pools  
*Cryptosporidium* outbreaks, 24  
diseases acquired from recreational water use, 580

- E. coli* 0157:H7 outbreaks, 24
- Hepatitis A virus outbreaks, 25
- historical background of poisoned drinking water, 26
- waterborne pathogens on the CDC threat list, 27
- WaterSentinel program, 27
- Waterborne pathogens and diseases. *See* Foodborne, waterborne, and agricultural diseases
- Weapons of Mass Destruction Civil Support Teams description, 422
- Weapons of Mass Destruction Medical Countermeasures Subcommittee
  - establishment and mission of, 14
- Wedum, Dr. Arnold
  - biosafety research, 516–517
- WEE. *See* Western equine encephalitis
- Weill Medical College
  - Bioterrorism and Epidemic Response Model, 433–434
- Wein, L.M.
  - botulinum toxin research, 339
- Welch, William
  - C. perfringens* research, 373
- West Nile virus
  - approximate geographic range, 2004 (figure), 594
  - bird deaths and, 53
  - case study and lessons learned, 53–54
  - isolation of, 594
  - spread across the United States, 1999–2004 (figure), 595
  - transmission, 595
- Western equine encephalitis
  - aerosol transmission, 254
  - antigenic subtypes, 244
  - components of the virus complex, 245–246
  - description, 242
  - diagnosis, 254–255
  - incidence, 243
  - incubation period, 254
  - isolation of, 242
  - laboratory-acquired infection, 257
  - medical management, 255–256
  - mortality rate, 243, 253–254
  - neurological sequelae, 253–254
  - passive immunization, 256–257
  - pathogenesis, 250
  - symptoms, 254
  - vaccines, 244, 256, 258–259, 480–481
  - vaccines available for VEE, EEE, and WEE viruses (table), 257
- Wheelis, M.
  - introduction of plague into a city by cadavers of plague victims, 2
- Wherry, W.B.
  - tularemia research, 168
- Whitewater Arroyo virus
  - description, 274
- Whitmore, Capt. Alfred
  - B. pseudomallei* isolation, 148
- Whitmore's disease. *See* Melioidosis
- WNV. *See* West Nile virus
- Working Group on Civilian Biodefense
  - plague treatment recommendations, 111–112
  - viral hemorrhagic fevers as potential biowarfare and bioterrorism threats, 277
- World Health Organization
  - biosafety risk group assignments, 518
  - brucellosis treatment recommendation, 192
  - estimate of the impact of an aerosol attack of Rift Valley fever, 276
  - estimate of the number of casualties and fatalities from agents delivered as aerosols from an aircraft, 426
  - Kosovo tularemia outbreak and, 55
  - Plague Manual*, 101, 110
  - plague reporting requirement, 101, 112
  - report of plague deaths in the Democratic Republic of the Congo, 101
  - smallpox eradication program, 9, 216, 228, 233
  - smallpox virus repository, 220, 481
  - Weekly Epidemiological Record, 101
- World War I
  - castor bean oil use as a lubricant, 324
  - German biological warfare program, 3, 45–46, 544
  - hantaviruses and, 275
  - influenza pandemic and, 588
  - melioidosis and, 151
- World War II
  - castor bean oil use as a lubricant, 324, 332
  - Colorado potato beetle outbreaks, 27
  - endemic plague and, 94
  - former Soviet Union's biological warfare program, 8
  - German biological warfare program, 4
  - Germany's field trials of foot and mouth disease dissemination, 28
  - glanders prevalence in horses in China, 126
  - hantaviruses and, 275
  - Japan's biological warfare program against China, 3–4, 544
  - Japan's poisoning of wells with *S. typhimurium* during, 23
  - melioidosis and, 149–150, 156
  - plague as a biological weapon, 95–96
  - Poland's biological warfare program, 4
  - Q fever and, 200–201
  - tularemia as a biological weapon, 168
  - tularemia outbreaks, 170
  - United Kingdom's biological warfare program, 4–5
  - United States' biological warfare research, 5–6
  - U.S. and British development of a ricin-containing bomb, 325
  - use of *B. mallei* as a biowarfare agent, 122
  - use of smallpox as a biological weapon, 220

## Y

- Y 62-63 virus. *See* Western equine encephalitis
- Y. pestis*. *See also* Plague
  - antibiotic resistance, 398
  - Japan's attacks against Chinese nationals with, 4
  - Y. pseudotuberculosis* and, 96–98
- Y. pseudotuberculosis*
  - Y. pestis* and, 96–98
- Yeaman, M.R.
  - Q fever treatment, 205
- Yellow fever virus
  - appointment of Maj. Walter Reed to the Yellow Fever Commission, 562
  - clinical manifestations, 280
  - description, 276
  - North Korean weaponization of, 276
  - petechial skin rash, 285
  - transmission, 276
  - transmission electron micrograph (figure), 277
  - vaccination for, 290, 450, 492
- Yellow rain. *See* Trichothecene mycotoxins
- Yeltsin, Pres. Boris (Russia)
  - former Soviet Union's biological warfare program, 338
- Yersin, Alexandre J.E.
  - discovery of *Y. pestis*, 93
- Yugoslavia. *See* Former Yugoslavia
- Yujiro, Maj. Wakamatsu
  - development of biological weapons for sabotage operations, 3–4

**Z**

Zimbabwe  
anthrax epidemic, 72

ISBN 978-0-16-079731-6



90000

9 780160 797316